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Mikaela Lee McKenney 
 
CORONARY ARTERY DISEASE PROGRESSION AND  
CALCIFICATION IN METABOLIC SYNDROME 
 
For years, the leading killer of Americans has been coronary artery 
disease (CAD), which has a strong correlation to the U.S. obesity epidemic. 
Obesity, along with the presence of other risk factors including hyperglycemia, 
hypercholesterolemia, dyslipidemia, and high blood pressure, comprise of the 
diagnosis of metabolic syndrome (MetS). The presentation of multiple MetS risk 
factors increases a patients risk for adverse cardiovascular events. CAD is a 
complex progressive disease. We utilized the superb model of CAD and MetS, 
the Ossabaw miniature swine, to investigate underlying mechanisms of CAD 
progression. We studied the influence of coronary epicardial adipose tissue 
(cEAT) and coronary smooth muscle cell (CSM) intracellular Ca2+ regulation on 
CAD progression. By surgical excision of cEAT from MetS Ossabaw, we 
observed an attenuation of CAD progression. This finding provides evidence for 
a link between local cEAT and CAD progression. Intracellular Ca2+ is a tightly 
regulated messenger in CSM that initiates contraction, translation, proliferation 
and migration. When regulation is lost, CSM dedifferentiate from their mature, 
contractile phenotype found in the healthy vascular wall to a synthetic, 
proliferative phenotype. Synthetic CSM are found in intimal plaque of CAD 
patients. We investigated the changes in intracellular Ca2+ signaling in 
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enzymatically isolated CSM from Ossabaw swine with varying stages of CAD 
using the fluorescent Ca2+ indicator, fura-2. This time course study revealed 
heightened Ca2+ signaling in early CAD followed by a significant drop off in late 
stage calcified plaque. Coronary artery calcification (CAC) is a result of 
dedifferentiation into an osteogenic CSM that secretes hydroxyapatite in the 
extracellular matrix. CAC is clinically detected by computed tomography (CT). 
Microcalcifications have been linked to plaque instability/rupture and cannot be 
detected by CT. We used 18F-NaF positron emission tomography (PET) to detect 
CAC in Ossabaw swine with early stage CAD shown by mild neointimal 
thickening. This study validated 18F-NaF PET as a diagnostic tool for early, 
molecular CAC at a stage prior to lesions detectable by CT. This is the first report 
showing non-invasive PET resolution of CAC and CSMC Ca2+ dysfunction at an 
early stage previously only characterized by invasive cellular Ca2+ imaging.  
 
Michael S. Sturek, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
 
The American Obesity Epidemic 
Merriam-Webster defines an epidemic as “an outbreak of disease that 
spreads quickly and affects many individuals at the same time”. With the 
sustained rise in obesity trends in the United States (Fig. 1.1), it is fair to say this 
is an American epidemic. The latest report from the Centers for Disease Control 
and Prevention revealed that more than one-third of American adults (34.9%) are 
obese (1).  
 While the American sedentary lifestyle undoubtedly plays a role in this 
epidemic, the homo sapiens’ “thrifty genotype” is also contributing to the cause. 
This “thrifty genotype”, first described in a classical review by Neel (2), is 
synonymous to a propensity to obesity. In his recent review, O’Rourke tells the 
story of the early South Pacific Polynesian people who battled through an 
energy-intensive lifestyle with limited food supplies. These events evolutionarily 
shaped the metabolism of these people so that in order to survive one must store 
large amounts of consumed calories in the form of adipose in just a short period 
of time (3). This adaptation allowed them to survive periods of famine. Fast 
forward our “thrifty genotype” to modern day where we have an overabundance 
of food and a lack of energy-intensive labor, both of which are fueling this 
American obesity epidemic. O’Rouke refers to this lifestyle as an “obesogenic” 
environment.  
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The Metabolic Syndrome 
This “obesogenic” environment has fueled a parallel catastrophic 
diagnosis for Americans – the metabolic syndrome (MetS). As defined in humans 
by the National Heart, Lung, and Blood Institute and the American Heart 
Association, MetS is a diagnosis of 3 or more of the following 5 risk factors: 
fasting plasma glucose ≥100 mg/dL, high density lipoprotein (HDL) cholesterol 
<40 mg/dL in men or <50 mg/dL in women, triglycerides ≥150 mg/dL, waist 
circumference ≥102 cm in men or ≥88 cm in women, and systolic blood pressure 
≥130 mmHg or diastolic blood pressure ≥85 mmHg (4). What is now recognized 
as MetS was originally characterized by Reaven in 1988 as resistance to insulin-
stimulated glucose uptake and hyperinsulinemia. Reaven made the statement 
that this cluster of risk factors plays a “significant role in the genesis of coronary 
artery disease (CAD) in the American population as a whole” (5). When a person 
presents with multiple MetS risk factors, their chances for adverse or even fatal 
cardiovascular problems are far greater than if presenting one risk factor alone 
(6) (Fig. 1.2, adapted from (6)).  
 
Coronary Artery Disease 
MetS increases an individual’s risk of developing CAD at least 2-fold (7) 
and CAD is estimated to be a diagnosis for >1 in every 3 American adults (4). 
CAD accounts for 1 in every 4 U.S. deaths, totaling to about 380,000 people and 
making it the leading cause of fatality in America (8). Health care services, 
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medications, and lost productivity for this disease alone cost the United States 
$108.9 billion every year (9).  
Macrovascular CAD is thickening of the artery wall due to an inflammatory 
response as a result of lipid accumulation. These conduit vessels are responsible 
for supplying oxygen-rich blood to the hard working muscle of the heart. There 
are three main coronary arteries: the left anterior descending (LAD) and left 
circumflex (CFX) that stem from the left ostium; and the right coronary artery 
(RCA) that stems from the right ostium (Fig. 1.3A&B). In the setting of CAD, 
when blood flow is limited due to plaque buildup, the lack of oxygen delivery to 
the cardiac muscle results in ischemia. In chronic and/or severe cases, when 
ischemia exceeds the critical threshold of myocardial oxygen demand, acute 
myocardial infarction (MI) can lead to fatality. MI can occur as a result of 
coronary plaque rupture do to plaque instability. Unsettling evidence shows that 
non-flow limiting lesions (typically <75% luminal narrowing), and therefore 
clinically insignificant lesions, are more likely to rupture due to their thin fibrous 
cap structure (10). These thin fibrous cap lesions are most common in 
hyperlipidemic patients with high dyslipidemia (10), both of which are risk factors 
for MetS (4;11).  
 
Coronary Epicardial Adipose Tissue 
 Along with the conventional risk factors of MetS, coronary epicardial 
adipose tissue (cEAT) is also guilty of contributing to the progression of CAD. 
The volume of cEAT (Fig. 1.3C) has been deemed an independent risk factor for 
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CAD by the Framingham heart study (12;13). While this fat depot is naturally 
occurring, it grows with chronic obesity (14). This cEAT has been directly 
correlated with CAD and the MetS risk factors by computer tomography (CT) 
(14;15) and echocardiography (16). Total epicardial adipose tissue (EAT) has 
been positively correlated with total cholesterol and low-density lipoprotein (17), 
both of which are MetS risk factors. 
More specifically, CAD lesions have been found predominately in regions 
of coronary arteries covered with cEAT (14;15;18;19). The basis of the 
hypothesis that cEAT contributes locally and detrimentally to CAD progression 
stems from pathophysiological evidence of increased proinflammatory, redox, 
endothelial cell, and angiogenic genes in the fat depot adjacent to known regions 
of CAD from patients undergoing coronary bypass (20). Prior to our recent pilot 
study (21), there has been no experimental evidence provided directly linking the 
role of the presence of cEAT in CAD progression. Furthermore, cEAT (22) and its 
associated inflammatory secretions (23) have been associated with another 
complication of CAD, vascular calcification.  
 
Vascular Calcification 
Vascular calcification can occur in either the intima or media of the 
vascular wall (Fig. 1.4A&B) and is made up of calcium in the form of 
hydroxyapatite (24). As its name suggests, medial calcification occurs in the 
media. Patients with renal failure, diabetes, aging, and osteoporosis are at risk 
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for medial calcification. This pathology leads to arterial stiffening and 
consequently hypertension and left ventricular hypertrophy (25).  
For the purpose of this thesis work, the interest lies with intimal vascular 
calcification specifically. Intimal calcification occurs only within atherosclerotic 
lesions and has been seen in histological samples as early as type IV lesions 
(26). Patients with dyslipidemia, hypercholesterolemia, hypertension, diabetes 
and obesity are at high risk for intimal calcifications (25). It is important to note, a 
patient with these risk factors would be diagnosed with MetS. The ultimate 
complication from intimal calcification is altered plaque stability and potential for 
rupture (25;27-29). 
In the past, it was thought that only advanced plaque in elderly CAD 
patients contained calcified lesions as result of a passive process (24). It is now 
known, however, that hydroxyapatite crystals can form as early as our third 
decade of life (26) and that calcification is an active and tightly regulated process 
(30). Of CAD patients who are classified as having intermediate risk by the 
Framingham Heart Study, 58% of women and 64% of men had coronary artery 
calcification (CAC) (4). Those with CAC have 4-10 times greater risk for a 
cardiovascular event (27). Specifically, CAC has been associated with plaque 
instability and rupture (28), further increasing mortality risk.  
Currently, computed tomography (CT) is used to non-invasively diagnose 
patients with CAC (31). Unfortunately, recent evidence shows that calcium 
deposition is occurring in the coronary arteries at a much early stage of CAD 
than that which CT can measure (26;32). Therefore, it is necessary to pursue an 
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alternative imaging technique that can measure microcalcifications. Positron 
emission tomography (PET) can detect molecular activity and calcium 
metabolism using the classic bone tracer 18F-NaF (33;34). Just as dental fluoride 
binds to hydroxyapatite in tooth enamel (Fig. 1.4C), 18F-NaF will bind directly to 
hydroxyapatite on the surface of bone (Fig. 1.4D(a)). The biggest strength of PET 
imaging is that is provides metabolic information. Areas of increased mineral 
metabolism and bone turnover will reveal increased 18F-NaF uptake on PET 
images (Fig. 1.4D(a)). While this molecular-level of activity can be observed with 
PET, simultaneous CT scans reveal no evidence of increased calcium deposition 
(Fig. 1.4D(b&c)) (35). Not only in bone, but research in both humans and swine 
has revealed increased 18F-NaF uptake in the soft tissues of the coronary 
arteries in the absence of any evidence of CAC by CT imaging (36;37). Recently, 
18F-NaF uptake has also been recognized as the first non-invasive method to 
identify high-risk patients for coronary plaque rupture (38). As stated by Beheshti 
et al., “molecular calcification as assessed by 18F-NaF likely will provide highly 
relevant information to our understanding of this common disorder before 
structural (macrocalcification) is detectable by standard CT techniques.” (36) 
 
Ossabaw Miniature Swine Model 
Our laboratory has characterized the Ossabaw miniature swine as a 
superb model of human MetS and mascrovascular CAD (39-44). The Ossabaw 
swine’s “thrifty genotype” allows them to store excess fat, which enabled them to 
survive during food shortages in their natural habitat off the coast of Georgia 
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(40). The pigs can fluctuate from a lean phenotype in a famine period (Fig. 1.5A) 
to a more obese phenotype in a feasting period (Fig. 1.5B). In captivity, when fed 
an excess-calorie atherogenic diet, Ossabaw develop all characteristics of MetS: 
insulin resistance, hyperglycemia, dyslipidemia, central obesity, and hypertension 
(45;46) (Fig. 1.5B).  
Swine have strikingly similar cardiovascular anatomy and physiology to 
humans (Fig. 1.3B) (40;47) . Along with MetS, Ossabaw develop mature (Fig. 
1.5C&D) and diffuse atheroma (40;42) including the advanced stage of intimal 
calcification (Fig. 1.5E) making them an ideal model of human CAD in the setting 
of MetS (42;43). This model is suitable for interventional and in vivo large animal 
studies, as well as for ex vivo and in vitro studies of cellular mechanisms (40).  
 
Coronary Smooth Muscle Cells 
 The walls of the coronary arteries are comprised of three distinct sections: 
adventitia, media, and intima (Fig. 1.3D&E). Boundaries between these sections 
are identified by the internal and external elastic laminae. The collagen-rich 
adventitia is separated from the media by the external elastic lamina. This medial 
layer is made up of quiescent coronary smooth muscle cells (CSM). These cells 
are of a contractile phenotype and do not replicate and migrate. The media and 
intima are separated by the internal elastic lamina. The intima of a healthy 
individual will be composed of only a thin, single layer of endothelial cells (barely 
visible in Figures 1.3D and 1.5C), which contribute substantially in regulating 
vasoreactivity. A CAD patient’s intimal layer will have damage to the endothelial 
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monolayer, which is a major trigger for encroachment of proliferative and 
migratory CSM (synthetic, sCSM), and a high presence of inflammatory cells 
such as monocytes, foam cells, and macrophages (48;49).  
CSM play a key role in the progression of CAD. Cytosolic Ca2+ signaling 
drives contraction of mature, differentiated CSM. Tight regulation of cytosolic 
Ca2+ is crucial for maintenance of a healthy coronary wall and coronary blood 
flow. Several Ca2+ transporters including channels, pumps, and exchangers are 
responsible for this role (Fig. 1.6).  Dysregulation of intracellular Ca2+ signaling is 
correlated with phenotypic modulation of CSM and dedifferentiation to a synthetic 
phenotype, sCSM (50). This plasticity allows CSM to adapt to changes in the 
local environment, i.e. elevated plasma low density lipoprotein (LDL) levels (50). 
Dedifferentiated sCSM are the cells that proliferate and migrate from the media 
to the arterial lumen where atherosclerotic plaque buildup of the intima occurs. 
It has been unveiled that sCSM will further modulate into an osteogenic 
phenotype (oCSM). This is supported by studies of smooth muscle phenotype 
switching to a state of “bone-like” gene expression, i.e. runt-related transcription 
factor 2 (RUNX2), and a loss of contractile proteins, i.e. smooth muscle myosin 
heavy chain (SM-MHC) (30;51). 
The Sturek laboratory has extensively studied CSM Ca2+ regulation in the 
setting of CAD (46). The plasma membrane Ca2+ ATPase (PMCA), a Ca2+ 
extrusion mechanism, appears to be the first impaired in early-stage CAD (52) 
along with a decrease in Na+-Ca2+ exchanger (NX) coupling (52). Ca2+ can also 
accumulate in the cytosol after being released from intracellular cellular stores 
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through ryanodine receptors (RyR). CSM may compensate for these changes by 
increasing sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression, 
thereby increasing Ca2+ buffering by the sarcoplasmic reticulum (SR), the primary 
intracellular Ca2+ store (53). However, there are conflicting data showing SERCA 
dysfunction in MetS Ossabaw (42) and atherosclerotic rabbits (54). Voltage-
gated Ca channels (VGCC), a Ca2+ influx mechanism, are downregulated in 
diabetic and dyslipidemic Yucatan swine (53;55). These data seemingly conflict 
with data from the Tune laboratory that show increased VGCC expression and 
current in MetS Ossabaw CSM (56); however, the discrepancy may be explained 
by the differing “diabetic milieu” in the studies. Another mode of Ca2+ influx, 
transient receptor potential canonical (TRPC1) expression has been correlated 
with CAD progression and CSM phenotype switching in humans (57). TRPC1 is 
also increased in MetS Ossabaw (44). In his 2011 Journal of Applied Physiology 
review of CSM Ca2+ regulation in disease and exercise, Sturek states: “This 
apparent discrepancy strongly reinforces the concept that the time course and 
severity of disease are crucial to interpretation of findings on Ca2+ regulation 
mechanisms.” (46). 
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The American obesity epidemic and its comorbidities (MetS and CAD) are 
the motivation for the following described research. Their implications on 
cardiovascular health were studied on cellular, tissue, and whole animal levels in 
order to better understand this fatal disease on a translational scale. This written 
body of work includes three independent studies that encompass the entirety of 
these introductory pages.  
 
Investigative Aims and Major Hypotheses 
1. Coronary epicardial adipose tissue contributes directly to CAD in Ossabaw 
swine and progression of CAD will be attenuated upon surgical removal of 
the local fat depot.  
2. 18F-NaF uptake in the coronaries of MetS Ossabaw with early stage 
atherosclerosis will be higher than that of lean Ossabaw and 18F-NaF 
uptake can be detected at a stage prior to that measurable by CT. 
3. CSM Ca2+ signaling and function are increased in “early” CAD, but 
significantly decreased in “later” stages of CAD progression. More 
specifically, fluctuation in VGCC activity plays a role in oCSM 
dedifferentiation and CAD progression to CAC.   
11 
 
Figure Legends & Figures 
 
Figure 1.1. Obesity trends among U.S. Adults. The American Obesity 
Epidemic is displayed across all 50 states with Indiana and the rest of the 
Midwest ranking among those with the highest occurrence of obesity in adults 
(58). This trend has evolved over the past 25 years and does not seem to be 
tapering off according to recent reports (1).  
 
Figure 1.2. An increased number of metabolic syndrome risk factors 
presented by a patient increases that patient’s risk for cardiovascular 
events. Relative to a patient presenting no metabolic syndrome (MetS) risk 
factors, a patient presenting only 2 risk factors will more than double their risk for 
a cardiovascular event. However, this patient is not clinically diagnosed with 
MetS because they do not present with 3 or more of the risk factors. A clinically 
diagnosed MetS patient has a more than 3-fold increase in risk of cardiovascular 
event relative to a none-presenting patient. Figure adapted from (6).  
 
Figure 1.3. Coronary artery anatomy and wall structure. A. Schematic 
representation of the heart and major epicardial coronary arteries. The aortic root 
is the origin of both the left ostium (LO) and right ostium (RO). From here, 
coronary arteries will supply oxygen-rich blood to the hard-working cardiac 
muscle of the ventricles. The LO leads to the left main which immediately 
branches into two of the main conduit coronary arteries, the left anterior 
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descending (LAD) and the circumflex (CFX) arteries. The LAD supplies to the 
septal, apical, and anterior portions of the left ventricle (LV) while the CFX 
supplies to the base and posterior portions. The RO leads to the right coronary 
artery (RCA) which supplies blood to the entire right ventricle. Coronary 
epicardial adipose tissue (cEAT) lies on top of these conduit vessels and its 
volume increases with MetS and obesity. B. The aortic trunk with conduits and 
branches dissected from the myocardium of an Ossabaw miniature swine.  C. A 
transversely dissected portion of the LAD from a MetS Ossabaw reveals the 
lumen of the artery with cEAT still intact. cEAT accumulates on the epicardial 
surface of the heart and increasingly encases the coronary vessels as coronary 
artery disease progresses. (59) D. Histology of a proximal coronary artery 
segment from a lean Ossabaw swine with the elastin stain, Verhoff-Van Gieson 
(VVG).  The collagen-rich adventitia (A) is separated from the media (M) by the 
external elastic lamina (EEL), which appears dark brown due to VVG staining. 
The media (M) is comprised of contractile coronary smooth muscle cells (CSM). 
The lumen (L) and media (M) are separated by an internal elastic lamina (IEL). 
Just on the luminal side of the internal elastic lamina is a thin layer of endothelial 
cells and a small number of synthetic CSM (sCSM) in healthy humans (48) and 
lean pigs. E.  Histopathology of proximal coronary artery from a MetS Ossabaw 
swine stained with VVG reveals a significantly thickened intima (I) which is 
comprised of sCSM and inflammatory cells. Note the lumen area is reduced and 
a necrotic core (NC) containing calcifications (Ca) lies in the 3 o’clock orientation.  
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Figure 1.4. Coronary artery disease progresses to a high-risk stage of 
calcium deposition within the atherosclerotic lesions. Vascular calcification 
has two distinct pathologies (25): A. medial calcification is designated by 
hydroxyapatite deposition within the medial layer of the artery wall. This 
pathology is extremely common in chronic kidney disease patients and is 
classified by vessel stiffness and hypertension. B. intimal or atherosclerotic 
calcification is designated by hydroxyapatite deposition within the intimal layer of 
atherosclerotic lesions in patients with coronary artery disease (CAD). Intimal 
calcification is associated with MetS and increases the risk for plaque instability 
and rupture leading to adverse cardiovascular events. With strong evidence that 
calcification occurs early in CAD and at a level below the detectable threshold of 
computed tomography (CT), researchers have turned to positron emission 
tomography (PET) with the efforts of detecting calcification at the molecular level 
using the long-known bone tracer, 18F-NaF. C. Fluoride (large blue circle) binds 
directly to hydroxyapatite by replacing the hydroxyl group (small white and blue 
circles). Calcium (red) is a major component of this bone mineral that is produced 
by osteogenic CSM (oCSM) within the arterial wall. (60). D(a). In this PET 
coronal image, 18F-NaF uptake can be seen in the bone tissues (black). This 
patient as a focal area of bone metabolism and calcium acitivty as indicated by 
increased 18F-NaF uptake at the site of a rib fracture (yellow arrow). D(b). A 
transaxial view of a simultaneous CT scan shows its high spatial resolution and 
vivid anatomical structures. D(c).  A hybrid image is constructed by overlaying 
the co-registered PET and CT scans to combine the high sensitivity of PET with 
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the high spatial resolution of CT. The metabolic activity seen on the PET scan is 
completely absent from the CT images. (35)  
 
Figure 1.5. Ossabaw swine fed an excess-calorie atherogenic diet develop 
obesity, metabolic syndrome, and coronary artery disease. Lean Ossabaw 
miniature swine (A) bodyweight will plateau, while Ossabaw fed an atherogenic 
diet (B) will continue to gain weight and present all risk factors of metabolic 
syndrome (MetS) (45). C. Proximal coronary artery histopathology with Masson’s 
trichrome staining reveals normal arterial wall structure and composition in lean 
Ossabaw. The collagen-rich (blue) adventitia (A) surrounds the medial layer (M) 
of the artery which is composed of contractile coronary smooth muscle cells 
(CSM) (red). A non-obstructed lumen (L) is also observed. D. Masson’s trichrome 
staining of proximal coronary artery from Mets Ossabaw with CAD reveals 
increased collagen (blue) deposition within the medial layer (M) of the arterial 
wall. Within the newly formed intimal layer (I), the CSM organization (red) has 
completely changed due to the transition of contractile cells to the synthetic 
phenotype which proliferates and migrates towards the lumen (L) and contributes 
to further collagen deposition (blue). E. Identical to human CAD pathology, MetS 
Ossabaw with later stage CAD will develop intimal calcification due to the 
transition of CSM to an osteogenic phenotype. The oCSM will deposit calcium in 
the form of hydroxyapatite into the extracellular matrix. Alizarin red staining of 
proximal coronary artery from MetS Ossabaw reveals a large calcified structure 
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(Ca, solid arrow) and spotty,  microcalcifications (Ca, dashed arrow) within the 
atherosclerotic intimal lesion (I).  
 
Figure 1.6. Several transporters including channels, pumps, and 
exchangers are responsible for regulation of intracellular Ca2+ signaling in 
coronary smooth muscle cells. Due to the high efficacy and potency of Ca2+ as 
a messenger in coronary smooth muscle cells (CSM), it is tightly regulated and 
kept at low levels in the cytosol (CaC) (~100 nM). Intracellular stores such as the 
sarcoplasmic reticulum will hold large capacities of Ca2+ (CaSR) which can be 
released to signal events such as contraction, transcription, proliferation, and 
migration. Two of the influx mechanisms that sit on the plasma membrane are 
the L-type voltage gated Ca2+ channel (VGCC) and the transient receptor 
potential canonical channel (TRPC). When Ca2+ comes into the cell it must be 
extruded back to the extracellular space or buffered into the internal stores. Two 
extrusion mechanisms also on the plasma membrane are the Na+-Ca2+ 
exchanger (NCX) and the plasma membrane Ca2+ ATPase (PMCA). Elevated 
CaC can also be buffered into the sarcoplasmic reticulum store by a similar pump 
that sits on the sarcoplasmic reticulum membrane, the sarco/endoplasmic 
reticulum Ca2+ ATPase (SERCA). CaSR can be released via release channels on 
the sarcoplasmic reticulum membrane called the ryanodine receptor (RyR). The 
interplay of these Ca2+ transporters is critical in the health and function of CSM. 
Loss of this tight regulation will lead to CSM dedifferentiation and progression of 
coronary artery disease.  
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Abstract 
Background: In humans there is a positive association between epicardial 
adipose tissue (EAT) volume and coronary atherosclerosis (CAD) burden. We 
tested the hypothesis that EAT contributes locally to CAD in a pig model. 
 
Methods:  Ossabaw miniature swine (n=9) were fed an atherogenic diet for 6 
months to produce CAD. A 15 mm length by 3-5 mm width coronary EAT (cEAT) 
resection was performed over the middle segment of the left anterior descending 
artery (LAD) 15 mm distal to the left main bifurcation. Pigs recovered for 3 
months on atherogenic diet. Intravascular ultrasound (IVUS) was performed in 
the LAD to quantify atheroma immediately after adipectomy and was repeated 
after recovery before sacrifice. Coronary wall biopsies were stained 
immunohistochemically for atherosclerosis markers and cytokines and cEAT was 
assayed for atherosclerosis-related genes by RT-PCR. Total EAT volume was 
measured by non-contrast CT before each IVUS. 
 
Results: Circumferential plaque length increased (p<0.05) in the proximal and 
distal LAD segments from baseline until sacrifice whereas plaque length in the 
middle LAD segment underneath the adipectomy site did not increase. T-
cadherin, scavenger receptor A and adiponectin were reduced in the intramural 
middle LAD. Relative to control pigs without CAD, 11β-hydroxysteroid 
dehydrogenase (11βHSD-1), CCL19, CCL21, prostaglandin D2 synthase, 
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gp91phox [NADPH oxidase], VEGF, VEGFGR1, and angiotensinogen mRNAs 
were up-regulated in cEAT. EAT volume increased over 3 months. 
 
Conclusion: In pigs used as their own controls, resection of cEAT decreased the 
progression of CAD, suggesting that cEAT may exacerbate coronary 
atherosclerosis. 
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Background  
 In most recent reviews of human cross-sectional studies (61-63), the 
amount of epicardial adipose tissue (EAT), measured either as thickness by 
echocardiography over the right ventricle or as total volume by computed 
tomography (CT) scans, correlated directly with coronary artery disease (CAD) 
burden.  Additionally, in prospective case-cohort (64) and in case-control (65) 
studies, EAT volume predicted future CAD events and myocardial ischemia.  
However, one report did not show that EAT volume added incremental predictive 
value over established CAD risk factors (66). 
 After regression analysis, EAT volume expansion in CAD occurs 
independently of associated increases in visceral abdominal and total body fat 
mass as well as changes in other CAD risk factors (62;63). This epidemiological 
evidence together with pathophysiological data showing increased chronic 
inflammatory cell infiltrates (67) and up-regulation of pro-inflammatory, redox, 
macrophage marker, and angiogenic gene expression specifically in EAT 
sampled from humans undergoing coronary artery bypass for severe CAD (20) is 
the basis for the hypothesis that EAT might contribute locally and detrimentally to 
coronary atherogenesis. However, to our knowledge, there is no direct 
experimental evidence that EAT plays a role in coronary atherogenesis. 
 Our laboratory has characterized Ossabaw miniature swine as a model of 
CAD. The “thrifty genotype” of Ossabaw swine has enabled survival in the feast 
and famine ecology, i.e. extreme variations in food availability, of Ossabaw Island 
(40). In the sedentary environment of captivity, our group induced CAD in this 
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breed of pigs by feeding them a hypercaloric, atherogenic diet (40;44) (42;59). 
This animal’s coronary arterial supply more closely resembles that of humans 
compared to rodent research models.  Additionally, rodent EAT is unpredictable 
in amount and not easily discerned, whereas the pig’s EAT is clearly demarcated 
macroscopically (40;59), can be imaged radiologically (40), and potentially might 
be amenable to surgical removal (68). We tested the hypothesis that surgical 
excision of EAT in direct contact with the coronary artery (cEAT) of pigs would 
attenuate underlying plaque progression in vivo. 
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Methods 
Animal Model and Protocol 
 We produced CAD in 9 castrated male Ossabaw miniature swine by 
feeding them 1000 g, once a day, of a high fat/cholesterol/fructose, atherogenic 
diet for 6 months starting at 6 months of age. The diet provided 16.3% kcal from 
protein, 40.8% kcal from complex carbohydrates, 19% kcal from fructose, and 
42.9% kcal from fat. Fat calories derived from a mixture of lard, hydrogenated 
soybean oil, and hydrogenated coconut oil.  It was supplemented with 2.0% 
cholesterol and 0.7% sodium cholate by weight (KT324, Purina Test Diet, 
Richmond, IN). Age- and gender-matched lean control swine were fed 750 g of 
regular chow (5L80, Purina Test Diet, Richmond, IN) containing 18% kcal from 
protein, 71% kcal from complex carbohydrates, and 11% kcal from fat once a 
day. All animals had free access to drinking water. After 6 months on the diet, CT 
was performed to quantify EAT surrounding the heart. Surgical excision of cEAT 
covering the middle segment of the left anterior descending (LAD) artery, which 
we termed selective coronary adipectomy, was then conducted via a 
thoracotomy, as described below, followed immediately by intravascular 
ultrasound (IVUS) quantification of CAD. Following the procedure, the same 
baseline diet was continued during a 3-month recovery period at the end of which 
identical CT followed by IVUS were performed prior to sacrifice and tissue 
collection. Control pigs did not undergo IVUS or adipectomy because they have 
been shown previously to develop minimal or no CAD over the time course of 
this experiment (42). In both adipectomy and control pigs at sacrifice, cEAT for 
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mRNA analysis was resected from the adventitial surface of the LAD just 
proximal to the middle LAD adipectomy site, and as a comparator, paracardial fat 
was sampled from the mediastinal surface of the pericardium towards the apex of 
the heart. Samples were stored at -80˚C. Biopsies of proximal, middle and distal 
LAD were taken and preserved for immunohistochemistry. All protocols involving 
animals were approved by an Institutional Animal Care and Use Committee and 
complied fully with recommendations in the Guide for the Care and Use of 
Laboratory Animals (69) and the American Veterinary Medical Association Panel 
on Euthanasia (70). 
 
Intravascular Ultrasound   
 Following an overnight fast, swine received a 2.2 mg/kg of xylazine 
(Webster Veterinary, Devens, MA) and 5.5 mg/kg of telazol (Fort Dodge Animal 
Health, Fort Dodge, IA) intramuscular injection to induce anesthesia. Swine were 
intubated and anesthesia was maintained with 2-4% isoflurane in 100% O2 as a 
carrier gas. The isoflurane level was adjusted to maintain anesthesia with stable 
hemodynamics. Heart rate, aortic blood pressure, respiratory rate, and 
electrocardiographic data were continuously monitored throughout the 
procedure. A 7F introducer sheath was inserted into the right femoral artery and 
heparin (200 U/kg) was administered under sterile conditions. A 7F guiding 
catheter (Amplatz L, sizes 0.75-2.0; Cordis, Bridgewater, NJ) was advanced to 
engage the left main coronary ostium.  A 3.2F, 30 MHz IVUS catheter (Boston 
Scientific, Natick, MA) was advanced over a 0.014 inch diameter percutaneous 
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transluminal coronary angioplasty guide wire (Boston Scientific, Natick, MA) and 
positioned in the LAD. Automated IVUS pullbacks were performed at 0.5 mm/sec 
in the LAD. Throughout the procedure angiography was performed to place the 
guiding and IVUS catheters in their desired positions. The IVUS catheter, guide 
catheter, and introducer sheath were removed and the right femoral artery 
ligated. The incision was closed and the animal was allowed to recover. 
Cefazolin (1000 mg; WG Critical Care, Lake Forest, IL) was given twice a day for 
six days following the procedure. 
 All IVUS pullback images were analyzed off-line (Windows Media Player, 
Microsoft) at 1 mm intervals. The LAD was divided into 3 segments: proximal (0-
15 mm), middle (15-30 mm) and distal (30-45 mm) with 0 mm starting at the 
bifurcation of the left main into LAD and circumflex. Three IVUS pullback images 
were captured per vessel segment. Using the Image-Pro Plus software (Media 
Cybernetics, Rockville, MD), lumen area (LA) was found by tracing the vessel 
lumen. From LA, lumen circumference (LC) was calculated for each vessel 
segment by the following formula: LC=2π [√ (LA/π)]. To derive wall coverage 
(WC) by plaque, the circumference of each cross-sectional image was divided 
into 16 equal segments. Percent wall coverage was calculated as (# segments 
containing atheroma ÷ 16) x 100. From the product of average WC x LC, a 
circumferential plaque length for each vessel segment was found. As an 
example, the following results are presented from a proximal coronary artery 
segment: 
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LA 21.40 mm2; LC 16.40 mm; WC 29.58%; circumferential plaque length = 
4.85 mm. Pullbacks were used for 7 out of 9 animals due to restrictions from 
vasospasms or lumen diameter. Using a 2-way analysis of variance (ANOVA), 
average circumferential plaque length per vessel segment was compared pre- 
and post-adipectomy.  
 
Selective Adipectomy 
Under general anesthesia, cardiovascular monitoring (both as described 
above), and using aseptic surgical techniques, all adipectomies were performed 
on the LAD with access via left thoracotomy by the cardiac surgeon. Figure 2.1A 
shows the anatomical structures and distribution of EAT over the epicardium of a 
representative pig heart ex vivo. A Thoratrak Retractor (Medtronic; Minneapolis, 
MN) was utilized for minimal rib spreading and as a base for the Octopus cardiac 
stabilizer (Medtronic; Minneapolis, MN) (Fig. 2.1B). The pericardium was opened 
and cradled to the drapes exposing the LAD.  The Octopus was then positioned 
to stabilize the middle LAD segment. Using the bifurcation of the left main into 
LAD and circumflex as the reference point, cEAT was excised sharply starting 15 
mm distal to this landmark for a distance of 15 mm along the length of the LAD 
and 3-5 mm on both the right and left lateral aspects of this part of the vessel 
(Fig. 2.1C). Non-absorbable Prolene sutures were placed to control epicardial 
venous bleeding from resected fat typically to the left side of the LAD. The 
ligatures demarcated this site for later tissue collection at sacrifice. When 
possible, the pericardium was loosely approximated with interrupted sutures. The 
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chest was then closed in layers in the standard fashion. Pleural air was 
evacuated by means of suction on an intrapleural red rubber catheter being 
withdrawn during a valsalva breath and closure of the chest wall musculature. 
One of the 9 animals succumbed intra-operatively from an acute myocardial 
infarction complicated by refractory ventricular fibrillation documented by ECG 
and by subsequent autopsy that showed acute LAD thrombosis.  There were no 
noticed post-operative complications in the remaining swine. 
 
Immunohistochemistry 
Sections of the LAD were prepared using techniques previously described 
by us (71). Samples of LAD were dissected and immersed in neutral-buffered 
10% formalin for a minimum of 24 h and then processed to paraffin embedment. 
The proximal, middle, and distal samples of LAD were obtained consistently from 
the same location in all pigs. Five-micrometer sections were cut with an 
automated microtome (Microm, Thermo Fischer Scientific, Bellefonte, PA), 
floated onto positively charged slides (Thermo Fischer Scientific), and 
deparaffinized. The slides were then steamed in citrate buffer at pH 6.0 (Dako 
target retrieval solution S1699; Dako, Carpenteria, CA) for 30 min to achieve 
antigen retrieval and subsequently cooled for 30 min. Next, the slides were 
stained manually with sequential Tris buffer or water wash steps performed after 
each protocol step. Sections were incubated with avidin biotin two step blocking 
solution (Vector SP-2001; Vector Laboratories, Burlingame, CA) to inhibit 
background staining and in 3% hydrogen peroxide to inhibit endogenous 
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peroxidase. Nonserum protein block (Dako X909; Dako) was applied to inhibit 
nonspecific protein binding. Immunostaining was performed using scavenger 
receptor A (SRA-ES; 1:100 dilution, Transgenic Inc. #KT-022), tryptase (1:600 
dilution, Dako #M7052), CD-3 (1:600 dilution, Dako #A0452), monocyte 
chemoattractant protein-1 (MCP-1; 1:100 dilution, PeproTech #500-P76), resistin 
(1:800 dilution, Phoenix Pharmaceuticals #H-02840), T-cadherin (1:1000 dilution, 
Abgent #CDH13, AP14346), adiponectin (1:200, Chemicon #MAB 3604) or tumor 
necrosis factor-alpha (TNF-alpha; 1:100 dilution, R&D #AF690). All the primary 
antibodies were diluted using antibody diluent (S0809; Dako) and were incubated 
with the tissue sections overnight at 4-C. After the appropriate washing was 
completed, sections were incubated with biotinylated antimouse or rabbit link 
secondary antibody and then peroxidase-labeled streptavidin (LSAB+ kit, 
peroxidase, K0690; Dako). Diaminobenzidine (K3468; Dako) was applied for 5 
min and allowed visualization of primary antibody staining. Sections were 
counterstained with Mayer hematoxylin for 1 min, dehydrated, and coverslipped. 
For negative controls, histological sections were prepared as described, but 
incubation in primary antibody was replaced with Tris buffer. 
Immunostaining analysis was performed in the entire vessel wall (i.e. 
intima to external elastic lamina boundaries) in order to quantify the presence of 
SRA, tryptase, CD3, MCP-1, resistin, T-cadherin, adiponectin or TNF-alpha. 
Sections were examined using an Olympus BX61 photomicroscope (Olympus, 
Melville, NY), and pictures were captured at 20x magnification. Image-Pro Plus 
(version 6.2.0.424; Media Cybernetics, Inc., Silver Spring, MD) was used to 
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identify and quantify the positive area of staining. Percent staining of the vessel 
wall was calculated from the data for positive staining and total area. An 
experienced investigator that was blinded to treatment group’s identities 
performed the selection of target areas, photography, and image analysis.  
 
mRNA Analysis 
mRNA Isolation. Approximately 0.2 to 0.5 g of frozen cEAT and 
paracardial fat from adipectomy and control animals was homogenized with 5 ml 
of a monophasic solution of phenol and guanidine isothiocyanate (TRIzol 
reagent, Invitrogen, Carlsbad, CA).  
  RT-PCR. The mRNA assay involved real-time quantitative PCR. 
Transcriptor First Strand cDNA synthesis Kit from Roche Diagnostics was used 
on equal quantities of RNA to prepare the complementary DNA (cDNA). The 
Roche Lightcycler 480 Real-time RT-PCR system and Roche’s Universal Probe 
Library of short hydrolysis Locked Nucleic Acid (LNA) dual hybridization probes 
combined with the primers recommended by their web-based assay design 
center [http://www.universalprobelibrary.com] were used for mRNA 
quantification. Integrated DNA Technologies (Coralville, IA) synthesized the 
primers. Twenty five genes related to atherosclerosis were selected (Table 2). 
Fifteen mRNAs were targeted for their roles in inflammation, 4 for their roles in 
oxidative stress as well as reactive oxygen species regulation and 6 in control of 
angiogenesis and endothelial cell function. In each assay, 55 ng per tube of total 
RNA (determined by absorption at 260 nm in a nano spectrophotometer) was 
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used. The data were obtained as crossing point values (Cp) obtained by the 
second derivative maximum procedure as described by Roche Applied Science 
technical notes LC10/2000 and 13/2001 [http://www.roche-applied-
science.com/sis/rtpcr/htc/index.jsp]. Relative quantification of the data was 
calculated using the absolute Cp values based on analyzing the same amount of 
total RNA in each assay as recommended by Bustin (72). 
 
Computed Tomography   
CT scans to quantify changes in EAT were analyzed by one observer. 
EAT was defined as fat between the inner surface of the visceral pericardium and 
epicardial surface of the myocardium (15;73). Paracardial fat was defined as fat 
lying within the mediastinum superficial to the parietal pericardium (15;73).  
Representative images are shown in Figures 2.2A-C. The pigs were scanned 
using a Philips Brilliance 64 detector scanner (Cleveland, OH) while sedated 
using 4% Isoflurane (Webster Veterinary, Devens, MA) supplied by mask. 
Imaging was performed with retrospective electrocardiogram (ECG) gating and 
without the administration of intravenous contrast from above the aortic arch to 
below the heart. Additional scan parameters included a 64 x 0.625 collimation, 
pitch of 0.2, rotation time of 0.4 seconds, 120 kVp, and 800-1000 mAs. Images 
were reconstructed with a slice thickness of 0.67mm and increment of 0.67mm 
using a CB filter. A batch was first created to ensure equal amounts of data were 
analyzed and included for each image set.  The baseline and pre-sacrifice 
images were then aligned side-by-side to ensure similar magnification and 
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orientation. Transverse images were analyzed by starting at the superior aspect 
of the atrial appendage.  Sternal, vertebral body and cardinal landmarks were 
utilized to insure similar alignment. The slice thickness of each image produced 
was 3 mm without overlap, yielding about 40 images per heart in each batch. 
Regions of interest (ROI) were drawn by hand using quantitative computer 
tomography angiography (Q-CTA) software on a Philips Extended Brilliance 
Workspace (Version 3.5) to include the entire heart.  Vessels leaving and 
entering the heart were included until they were noticeably detached from the 
heart. The Hounsfield unit (HU) value is similar for blood, muscle, and soft tissue, 
thus making the vessels appear as part of the heart until a visible distance is 
evident between the heart and the vessel.  In all cases vessels were split in the 
ROI through their center as the pericardium encapsulates the most proximal 
regions of the vessels leaving and entering the heart.  The software highlighted 
all tissue that matched the HU intensity of a reference ROI drawn in known 
subcutaneous fat (at the level of the carina). The fat area measurements of the 
images were then multiplied by their slice thickness to determine fat volume. 
Volumes of EAT were compared before adipectomy and at the end of the 
recovery period. Inter-operator coefficient of variation was 6.2%, while intra-
operator variation was 1.0%.        
 
Statistics    
 Statistical analysis was performed via Microsoft Excel 2010, utilizing 
ANOVA, regression analysis and post hoc 1- and 2-tailed paired student t-tests 
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to examine significance. All values are given as mean ± SEM. A p value <0.05 
was considered statistically significant. 
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Results 
Metabolic Characteristics        
  At adipectomy, pigs on the atherogenic diet had developed CAD 
and its risk factors including hypertension, obesity, increased LDL/HDL ratio, 
insulin resistance, glucose intolerance and increased triglyceride levels 
compared to age-matched lean controls (Table 2.1). Other than the increase in 
body weight, these characteristics remained constant during the 3 month 
recovery following adipectomy (data not shown). 
 
IVUS   
Representative IVUS images in Figure 2.3 show a normal coronary lumen 
(A) as well as partial (B) and complete circumferential (C) neointimal plaque 
formation. The results of IVUS pullbacks revealing atherosclerosis in each 15 
mm length proximal, middle and distal portions of the LAD from its origin are 
shown in Figure 2.3D. Over 3 months, baseline mean circumferential plaque 
length in the proximal LAD increased from 4.45±0.54 to 8.24±1.03 mm (p<0.05, 
Two-way ANOVA and Bonferroni post-hoc) and in the distal LAD from 1.98 ± 
0.35 to 5.74± 0.75 mm (p<0.05, Two-way ANOVA and Bonferroni post-hoc). By 
contrast, circumferential plaque length in the middle LAD increased from 
5.60±0.90 to 7.64±1.03 mm, which was not statistically different (p>0.05, Two-
way ANOVA and Bonferroni post-hoc). There was no difference between 
baseline mean proximal and middle LAD plaque lengths (p=0.26), whereas 
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middle LAD was higher than distal LAD (p<0.05) and proximal was also greater 
than distal (p<0.05).  
 
Immunohistochemistry 
On light microscopy of the LAD middle segment sections, a thinner layer 
of cEAT covered the adventitia than the adjacent two segments, suggesting no 
regrowth of remnant fat 3 months after adipectomy. Figure 2.4A shows 
representative photomicrographs of the presence, distribution and intensity of 
immunostaining of T-cadherin, SRA and adiponectin in the three segments of the 
LAD. T-Cadherin was strongly positive in the endothelial layer, but also present 
in the sub-endothelial neointima in proximal and distal LAD, but to a lesser extent 
in the middle vessel wall. SRA was present in the endothelial layer and 
neointima. Adiponectin was present in the endothelial layer and very dispersed 
over the media. As shown in Figure 2.4B (panel A), when these markers in all 
samples were quantitated, there was a significant reduction in mean percentage 
area of T-cadherin staining in the intima-media from 4.77±0.92% in the proximal 
and 4.71±0.66% in the distal LAD segments to 2.67±0.66% in the middle LAD 
(proximal to middle LAD p<0.05 and distal to middle LAD p<0.05 using 2-tailed t 
tests). SRA staining (Fig. 2.4B, panel B) was 0.73± 0.25% in the proximal LAD 
and 0.26±0.08% in the middle LAD which was significantly different (p<0.05) by a 
1-tail t test with a trend towards significance (p= 0.07 in a 2-tailed t test), and 
0.74±0.45% in the distal LAD which although higher than the middle LAD was not 
significantly different.  Adiponectin staining (Fig. 2.4B, panel C) was significantly 
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lower in the middle LAD 3.28±1.04% versus the proximal 8.94±2.32% (p<0.05 in 
a 1-tailed t test versus a trend for significance p=0.08 in a 2-tailed t test). In the 
distal LAD, adiponectin measured 5.12±1.57%, which was not different to either 
the proximal or middle LAD. There were no differences in coronary wall percent 
staining for tryptase, CD3, TNFα, MCP-1 and resistin between the proximal, 
middle and distal LAD. 
 
CT Quantification of Epicardial Fat 
 In Figure 5, CT scans done on 6 of the 8 surviving swine showed an 
increase in total EAT volume from 9.7 ± 1.1 cm3 at adipectomy to 13.5 ± 0.7 cm3 
at time of sacrifice, representing a 39% increase (p = 0.006) over 3 months. Due 
to inadequate numbers of data points, CT data could not be correlated with the 
IVUS data to determine if a relationship existed between changes in EAT volume 
and total plaque burden. 
 
Gene Expression  
 Table 2.2 shows the expression in cEAT and paracardial fat of genes 
linked to atherogenesis, namely those involved in inflammation, reactive oxygen 
species and redox reactions, angiogenesis and endothelial cell function. The 
data in each fat depot are expressed as the ratio of experimental to control pig fat 
depots. In EAT, there were significant and substantial fold increases in mRNA 
expression of pro-inflammatory 11β-hydroxysteroid dehydrogenase (11βHSD-1), 
CCL19, CCL21 and PGD2S; anti-inflammatory adiponectin; pro-oxidant 
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gp91phox [NADPH oxidase], angiogenic VEGF and VEGFGR1 and 
vascoconstrictive angiotensinogen. There were no changes in pro-inflammatory 
toll-like receptor 4 [TLR4], CCR7, TNFα, IL-1β, IL-6, IL-8, leptin, Unc5b, netrin-1 
and NGF; redox genes eNOS, superoxide dismutase [SOD], cyclooxygenase 2 
and cytochrome oxidase; and vasoconstrictor endothelin-1 and vasodilator 
adenosine receptor 1.By contrast, in paracardial fat relative to cEAT, 11βHSD-1 
and CCL21 were normal; CCL19, PGD2S, adiponectin pro-oxidant gp91phox 
[NADPH oxidase] VEGF, VEGFGR1 and angiotensinogen were up-regulated to 
much lesser degrees; and the remaining genes were similar except for TLR4 and 
endothelin-1 which were modestly (~2 fold) increased. 
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Discussion 
We present experimental evidence that, in Ossabaw miniature swine, 
selective surgical excision of adipose tissue in direct contiguity with one of the 
epicardial coronary arteries attenuated the progression of atherosclerosis, thus 
supporting the hypothesis that cEAT could contribute to underlying coronary 
atherogenesis (68). The findings are applicable to the early stages of CAD 
because of the relatively young age of the animals, the short duration of 
atherogenic diet feeding, and the lack of observed flow-limiting coronary stenosis 
typical of advanced clinical disease. We acknowledge the substantially high LDL 
cholesterol levels (>500 m/dL) in the obese group. We have conducted other 
studies in which the LDL was ~250 mg/dL (e.g. (42;44)) for a longer duration, 
which yielded substantial coronary atherosclerosis. We predict a similar result of 
adipectomy. This very high LDL cholesterol level for a short duration is similar to 
LDLR-/- humans, who have substantial atherosclerosis. Horton and colleagues 
refer to this phenomenon as the effect of cumulative LDL cholesterol in g/dL-
years (74). 
 We showed that in the middle LAD at the adipectomy site, progression of 
CAD was not significant compared to the significant increases in circumferential 
plaque in the adjacent, unperturbed proximal and distal segments. Thus, in the 
middle LAD segment, the increase in mean plaque length was 1.4-fold compared 
to 1.9- and 2.9-fold in the proximal and distal LAD, respectively. There were 
higher mean values and greater variability in baseline plaque length in the middle 
compared to the proximal and distal segments at the time of adipectomy, 
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suggesting that the attenuated progression of atheroma could have been the 
consequence of higher initial plaque thickness at the inception of the protocol. 
However, a two-tailed, paired t-test did not indicate that this baseline difference 
was statistically significant (p=0.26). The reason for the variability in the middle 
LAD plaque dimensions is not clear, since prior studies have indicated that mean 
plaque burden is greatest proximally and decreases distally in the LAD (42). One 
possibility is that adipectomy could have perturbed underlying plaque structure or 
vasomotor responses and interfered with IVUS measurements performed under 
heparin immediately after adipectomy. However, we have recently shown that 
cEAT has uniformly adverse effects on coronary artery function (75;75), in 
contrast to protective effect of PVAT in the aorta and other arteries. This explains 
why we observed no adverse mechanical changes after adipectomy.   
We resected fat from one coronary artery for several reasons. Resection 
of as much fat as possible off the entire myocardium was not technically possible 
in vivo. cEAT on the LAD was the most accessible site within the operative field 
of exposure compared to either the circumflex or right coronary arteries, which 
would lessen both intraoperative trauma, morbidity and mortality, and the risk of 
post-operative complications. This strategy targeting one rather than two vessels 
was subsequently vindicated by the low intraoperative mortality (1 of 9 pigs) and 
no noticed post-operative complications. Finally, the longitudinal time course of 
the experiment enabled the pigs to act as their own controls.        
 Immunoreactivity for T-cadherin was predominantly localized to the 
endothelium as previously established (76), but also to the neo-intima. It is 
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considered to be a marker of active atherosclerosis (76) and a major receptor for 
adiponectin in the vasculature (77). T-cadherin and SRA, the scavenger receptor 
for LDL-cholesterol on plasma membranes of plaque macrophages and foam 
cells (78;79), were reduced in the middle LAD intima-media implying less 
atherogenesis. Paradoxically, anti-inflammatory immunoreactive adiponectin in 
the same LAD segment was reduced significantly by 68%, despite a ~7-fold 
upregulation of adiponectin mRNA expression in overlying cEAT; thus, one might 
surmise that adiponectin released by epicardial adipocytes might not have been 
able to penetrate the coronary wall if such a mechanism exists. While a majority 
of the literature describes a decrease in adiponectin expression in CAD patients, 
we speculate that the 6.7-fold increase in obese pig cEAT mRNA was a 
compensatory response and that there must be some block in mRNA translation. 
We have previously reported that serum adiponectin is decreased in obese 
versus lean Ossabaw swine (41). On the other hand, there were no changes in 
vessel wall CD3 (a T lymphocyte cell marker), tryptase (a basophil marker), 
TNFα, MCP-1, and resistin.  
The mechanisms whereby selective adipectomy might have attenuated 
the progression of CAD remain to be established, but hypothetically include (i) 
the removal of factors generated by cEAT that could contribute to atherogenesis 
by direct diffusion through the porous adventitia into the coronary intima-media 
(73), such as reactive oxygen species (ROS) and pro-inflammatory cytokines 
and/or (ii) the disruption of vasa vasorum in the adventitia and in the closely 
adjacent cEAT (80), which might interfere with vasocrine signaling of atherogenic 
44 
 
adipokines (73) and restrict mononuclear cell access into the intima-media. The 
evidence for these suppositions includes the fact that relative to control cEAT, 
there was significant up-regulation in atherosclerotic cEAT of pro-inflammatory 
11βHSD-1, CCL19, CCL21 and PGD2S; gp91phox [NADPH oxidase],a major 
source of vascular ROS; VEGF and VEGFGR1, which partake in vasa vasorum 
neogenesis and angiotensinogen, which promotes endothelial dysfunction and 
vasoconstriction. Similar to our current findings in pigs, we reported 3-fold up-
regulation of 11βHSD-1 gene expression in human EAT adjacent to severe CAD 
over controls without CAD (20). Pharmacological inhibition of 11βHSD-1 
prevented aortic plaque progression in a murine model of atherosclerosis, 
suggesting that 11βHSD-1 may play a role in atherogenesis (81).  Lymphoid 
chemokines CCL19 and CCL21 are crucial for the recruitment of circulating naive 
T cells into lymph nodes. Increased levels of CCL19 and CCL21 have been 
reported within the atherosclerotic lesions of ApoE-/- mice, in human 
atherosclerotic carotid plaques, and in plasma of CAD patients (81). In mice, 
PGD2S deficiency induces obesity and facilitates aortic atherosclerosis (82), 
suggesting it is normally protective and anti-atherogenic in this species. The role 
of PGD2S in porcine atherosclerosis has not been reported, but -regulation of 
PGD2S in EAT in our study was associated with amelioration of atherosclerosis, 
suggesting the possibility that this pro-inflammatory prostanoid might otherwise 
be harmful either alone or in conjunction with other adipokines. No changes were 
observed in cEAT in the expression of TLR4 and acute phase cytokines TNFα, 
IL-1β, IL-6, IL-8 as well as the anti-oxidant genes eNOS and SOD. Finally, the 
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enhanced expression of a selected array of pro-atherosclerotic genes in cEAT 
over paracardial fat attests to the relative specificity of the genomic response of 
cEAT associated with CAD that has been similarly documented in humans with 
CAD (20).  
 Epicardial fat volume determined by sequential CT scans significantly 
increased over 3 months of hypercaloric feeding under the same conditions 
previously shown to result in major expansion of visceral retroperitoneal and 
intraperitoneal as well as subcutaneous abdominal fat depots in the same animal 
model (39). Although our experimental design using pigs as their own controls in 
a longitudinal study has its strengths, there are also limitations in the lack of 
sham-adipectomies in age- and gender-matched pigs fed hypercaloric 
atherogenic diet. Future studies should employ sham-operated animals; 
randomization of experimental and control pigs; blinding of both the 
ultrasonographer and two independent IVUS data analysts to the pig group 
designation; reversing heparin anti-coagulation during IVUS with protamine 
sulphate so that IVUS can be done before surgery; CT scanning using radio-
contrast dye to delineate the coronaries and to quantitate cEAT area around 
coronary plaques per se rather than EAT covering the entire myocardium; and 
immunohistochemical and mRNA analysis of cEAT and the coronary wall for 
expression of genes and proteins known to be important mediators of or 
participants in atherogenesis. To make these studies more translatable to clinical 
treatment, more clinical outcomes studies in the swine model would be helpful, 
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for example, monitoring hard clinical endpoints such as MI, fatal events, etc. over 
a longer duration.  
Our translational research project was done using experimental conditions 
prohibited in man by obvious ethical constraints and, with the provisos noted 
above, supports the human epidemiological evidence for a direct relationship 
between EAT and CAD. At this juncture and until more rigorous evidence is 
available one way or the other, it is premature to advocate an adipectomy as 
surgical treatment to attenuate the progression of CAD. Rather, it would be more 
appropriate from a clinical point of view if non-invasive methods were devised to 
shrink epicardial fat volume to serve the same beneficial purpose. In this regard, 
weight loss by caloric restriction and/or exercise in obese human subjects is 
associated with shrinkage of EAT volume by 9-32% of baseline in different 
reports (68;83), but it is not known whether this is accompanied by decreases in 
chronic inflammation in EAT or reduction in CAD burden (42). 
 
Conclusions  
The results of our pilot study are consistent with the hypothesis that 
selective coronary artery adipectomy attenuates the progression of early 
atherosclerosis, setting the stage for performing definitive future studies using 
sham operation controls. These studies will determine whether coronary 
adipectomy attenuates stable atherosclerotic plaques typically found in clinically 
advanced disease. 
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Figures & Tables 
 
Figure 2.1. Removal of coronary epicardial adipose tissue from the left 
anterior descending artery. A. Ossabaw heart (left anterior view) ex vivo. a. 
epicardial adipose tissue; b. left anterior descending artery; c. circumflex artery; 
d. left ventricle; e. pulmonary artery; f. aorta. B. Adipectomy procedure with 
Octopus stabilizing the myocardium and left anterior descending (LAD) segment.  
C. Surgical landmarks for excision of epicardial adipose tissue; RC, right 
coronary artery; LAD, left anterior descending artery; CFX; circumflex artery. 
 
Figure 2.2. Epicardial fat computed tomography imaging. Transverse slices 
were taken at the level of the carina, approximately midway between the base 
and apex of the heart. A. Landmark CT: a. subcutaneous adipose tissue; b. 
sternum; c. heart; d. lungs; e. bronchi. B. Representative ROIs: a. subcutaneous 
reference ROI; b. ROI drawn to encapsulate pericardium (fat inside ROI 
considered epicardial fat); C. CT image after fat analysis (maroon=fat); a. ROI 
arrows drawn to show epicardial fat locations; b. paracardial fat. CT = computed 
tomography, ROI = region of interest.         
 
Figure 2.3. Intravascular ultrasound images and analysis. A-C: IVUS 
images, distance between white dots =1.0 mm. A. Normal vessel with no intimal 
thickening; a. guidewire artifact b. IVUS catheter c. clear lumen d. lumen of 
parallel vessel. B. Analysis example; a. atheroma covering 3 segments of a 16 
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segment designation ~ 19%. C. a. Concentric neointimal ring of atheroma. D. 
Circumferential plaque length in each 15 mm of proximal, middle and distal left 
anterior descending coronary artery (LAD) at the time of adipectomy (survival, 
lower line) and at sacrifice (3 months later, upper line). Values are mean ± SEM  
for 7 pigs. Asterisk indicates p<0.05 between upper and lower proximal and distal 
LAD portions. 
 
Figure 2.4. Left anterior descending artery immunostaining for 
inflammatory markers. A: Representative photomicrographs of brown 
immunostaining for T-Cadherin [A, upper panels], SRA [B, middle panels] and 
Adiponectin [C, lower panels] in the designated LAD segments. Arrows point to 
brown positive stains in the endothelial and sub-endothelial neo-intima for each 
marker. Scale bar=500 microns. B: Percent immunohistochemical staining of the 
proximal, middle and distal 15 mm segments of left anterior descending coronary 
wall intima-media for a; T-Cadherin, b; SRA and c; adiponectin. The same letters 
(a-a, b-b) indicate that the mean ± sem in the segments are significantly different 
(n = 8 separate samples from each segment, p<0.05).     
 
Figure 2.5. Epicardial adipose tissue volumes of swine on high-fat diet 
before adipectomy and 3 months after the procedure. Letter a indicates 
significant difference, p<0.05. 
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Figure 2.1 
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Figure 2.2 
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Figure 2.3 
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Figure 2.4 
 
  
54 
 
Figure 2.5 
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Table 2.1. Metabolic characteristics of Ossabaw swine.  
Parameter                                        Obese (n=9)          Lean (n=9)        P value  
Weight at Adipectomy (kg)      77 ± 3      N/A                       N/A 
Weight at Sacrifice (kg)      91 ± 1      54 ± 2       < 0.001 
Total Cholesterol (mg/dL)      576 ± 40      57 ± 6               < 0.001 
Fasting Triglycerides (mg/dL)      108 ± 21      32 ± 3               < 0.001 
LDL (mg/dL)      502 ± 36      33 ± 1               < 0.001 
HDL (mg/dL)      53 ± 7      24 ± 2               < 0.005 
LDL/HDL Ratio      11 ± 2      1 ± 0.1              < 0.001 
Fasting Glucose (mg/dL)      80 ± 5      73 ± 6                  0.334 
Plasma Glucose Peak (mg/dL)      820 ± 35      527± 24          < 0.001 
Plasma Glucose AUC      17138 ± 1004    9274 ± 377      < 0.001 
Fasting Insulin (µU/ml)      21 ± 6      5 ± 1         0.020 
Plasma Insulin Peak (µU/ml)      172 ± 19      33 ± 4             < 0.001 
Plasma Insulin AUC      4413 ± 432      667 ± 121      < 0.001 
Systolic Blood Pressure (mmHg)      138 ± 2      110 ± 3             <0.001  
Diastolic Blood Pressure (mmHg)      79 ± 2      67 ± 2               <0.030  
Adipectomized obese swine were age matched to lean swine. Values for 
adipectomized swine were obtained just prior surgery (n=9), except for body 
weight at sacrifice (n=8). AUC = area under curve, HDL = high density 
lipoprotein, LDL = low density lipoprotein 
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Table 2.2. Ratio of gene expression in fat from obese and lean Ossabaw pigs.  
                   
                 Ratio of obese/lean 
mRNA       Epicardial Fat         Paracardial Fat   
Inflammatory adipokines or proteins associated with inflammation  
11β HSD-1    16.0*   1.2 
CCL19    14.0*   4.4* 
Adiponectin      6.7*      5.0* 
Prostaglandin D2 synthase    5.3*   3.0* 
CCL21      3.1*   1.0 
TLR4       1.8   2.0*  
IL-6       1.7   1.8 
NGF       1.6   1.6 
IL-8       1.6   1.4 
Unc5b       1.4   1.1 
Netrin-1      1.3   0.6 
CCR7       1.2   0.8 
TNF       1.1   1.7 
IL-1β       0.8   0.6 
Leptin       0.7   1.5 
Oxidative stress/reactive oxygen species regulation  
gp91phox [NADPH oxidase] 72.0*   5.4* 
SOD       2.0   1.5 
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cytochrome C oxidase    1.5   1.5 
cyclooxygenase 2     2.2   1.1 
      Angiogenesis and endothelial cell function   
VEGFa    16.0*   4.3* 
Angiotensinogen     5.3*   1.6     
VEGFGR1      4.3*   4.3* 
Endothelin-1      2.5   1.7 
 eNOS      1.1   1.4 
adenosine receptor 1    0.7   0.9                   
mRNA ratios of obese (n=8) to lean (n=8) swine. 
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Abstract 
Objectives: We sought to validate 18F-NaF positron emission tomography (PET) 
imaging as a diagnostic tool for early coronary microcalcification in a preclinical 
swine model of metabolic syndrome (MetS) and coronary artery disease (CAD). 
We compared multiple imaging modalities: PET, computed tomography (CT), 
IVUS, and histopathology for their sensitivity to measure early coronary artery 
calcification. 
 
Background: 18F-NaF uptake has been investigated as an in vivo biomarker of 
early vascular calcification and high-risk atherosclerotic plaque in humans. 
Vascular calcification increases risk of fatal cardiac events in CAD patients, thus 
making early diagnosis and clinical intervention extremely important. To our 
knowledge, no studies to date have investigated early calcification before 
clinically significant CAD.  
 
Methods: MetS Ossabaw swine (n=11) with early-stage CAD underwent ECG-
gated 18F-NaF PET/CT scans followed by IVUS and histology. Both global 
cardiac and coronary tracking techniques were used to measure 18F-NaF uptake. 
Total calcium deposition was measured in the left ventricle by an HCl extraction 
assay. Finally, specimens of the proximal right coronary artery were obtained to 
histologically examine CAC.   
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Results: MetS swine (n=11) with CAD had almost 2-fold increased 18F-NaF 
uptake in the conduit coronary arteries (p<0.05) compared to lean (n=3), as well 
as 2.5-fold increased global molecular calcium score (p<0.05). IVUS identified a 
local calcified lesion in 1 MetS pig. All pigs, lean and MetS, had Agatston calcium 
scores of 0. Histological staining of proximal right coronary specimens revealed 
microcalcifications present in 45% of MetS pigs. 
 
Conclusions: We have provided evidence that 18F-NaF uptake is a marker of 
early coronary artery calcification. This uptake occurs at a stage of CAD and 
microcalcification prior to clinically significant, ossified lesions that can be 
detected by IVUS and CT imaging.  
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Background 
 In the United States, coronary heart disease alone caused 1 in every 6 
deaths in 2010, which translates to approximately 380,000 total deaths per year. 
Annually, an estimated 620,000 Americans suffer a new coronary attack, while 
295,000 have recurrent attacks, and an estimated additional 150,000 Americans 
suffer from silent first myocardial infarctions (4).  
It is widely accepted that coronary artery calcification (CAC) contributes to 
local inflammation and, therefore, coronary artery disease (CAD) progression 
(84-87). CAD must be recognized as a dynamic, progressive disease involving 
various stages of plaque severity (43;88) that if left untreated could result in 
plaque rupture and a potentially fatal cardiac event. The direct cause of plaque 
rupture is still poorly understood, however, evidence suggests early CAC within 
the atherosclerotic plaque contributes to this increase in patient cardiovascular 
risk due to plaque instability (29;89-97).  
 Currently, the method for the identification of at-risk patients is computed 
tomography (CT) imaging and Agatston scoring for coronary calcium (31). While 
its high spatial resolution provides information on plaque morphology and the 
presence of macrocalcifications, CT lacks the ability to provide metabolic 
information from activity occurring at the molecular level of microcalcifications, 
which are known to be a higher risk to the patient. This shortcoming in CT 
imaging forces clinicians to rely on information from consecutive scans over a 
period of time to yield CAC progression data (32). By using an imaging modality 
that provides metabolic activity information in one imaging session such as 
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positron emission tomography (PET), the number of scans and, therefore, 
amount of radiation exposure, could be minimized in patients. Also, it is unclear 
at what threshold microcalcifications exceed the necessary density to become 
macrocalcifications that can be quantified by CT. If microcalcifications indicate 
high-risk, vulnerable plaque, we need an alternative method for identifying these 
patients sooner than currently possible with CT.  
 Areas of active microcalcification contain hydroxyapatite, a main 
component of bone (98). This fact allows use of the well-recognized bone tracer, 
18F-NaF, as a biomarker of active plaque calcification (33;34). Combining the 
strengths of both techniques, PET/CT hybrid imaging can be performed to obtain 
images with both high spatial resolution and high sensitivity for mineral 
metabolism and microcalcification activity.   
18F-NaF has previously been identified as a biomarker of active tissue 
calcification that can predict atherosclerotic disease progression in various 
vascular tissues (36;99-103), but recently it has been recognized as the first non-
invasive method to identify high-risk patients for coronary plaque rupture (38). 
Joshi and colleagues (26) correlated patients with myocardial infarction to the 
highest coronary 18F-NaF uptake in culprit vessels. This striking advancement in 
the field is consistent with the hypothesis that 18F-NaF is an early marker of CAC 
and predictor of plaque instability. More definitive validity would have been 
provided by invasive coronary measures, i.e. histopathology, or demonstration 
that 18F-NaF uptake occurs before CAC.  
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We have therefore conducted a study in our preclinical swine model that 
has coronary atherosclerosis in all stages of development from clinically 
insignificant fatty streaks through necrotic, flow-limiting lesions with 
macrocalcification detectable by intravascular ultrasound (IVUS) (42;43). We 
performed invasive measures of CAC (IVUS, histopathology) to correlate with 
18F-NaF uptake in the coronary arteries. We tested the hypothesis that 18F-NaF 
PET imaging can detect CAC earlier than the current gold standard non-invasive 
CT scanning and invasive IVUS. We concluded that 18F-NaF uptake into the 
conduit coronary arteries indicates an early stage of active calcium deposition 
and metabolism at sites of CAC that are too small to be detected by both CT and 
IVUS imaging, but correlates with plaque burden.  
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Methods 
Animal Care  
This protocol was approved by the Indiana University School of Medicine 
and the Purdue University Animal Care and Use Committees, and was 
conducted in accordance with NIH and USDA guidelines on animal care and use. 
Female Ossabaw miniature swine (n=11) were assigned to an excess-calorie, 
atherogenic custom diet for 6 months (16.3% kcal from protein, 40.8% kcal from 
complex carbohydrates, 19% kcal from fructose, and 42.9% kcal from fat). 
Animals were fed 1,500 grams once daily. The feed was supplemented with 
cholesterol (2.0%), hydrogenated coconut oil (4.70%), hydrogenated soybean oil 
(8.40%), cholate (0.70%), and high fructose corn syrup (5.0%) by weight 
resulting in the induction of metabolic syndrome (MetS) and CAD (40;42-45) 
(Table 3.1). Age- and gender-matched lean pigs (n=13) were fed 750 grams of a 
standard chow (5L80, Purina Test Diet, Richmond, IN; 18% kcal from protein, 
71% kcal from complex carbohydrates, and 11% kcal from fat). All animals were 
kept in individual housing with free access to drinking water and a 12 hour light-
dark cycle.  
 
18F-NaF PET/CT imaging & analysis  
After 6 months on the diets, pigs underwent simultaneous PET/CT scans. 
The protocol is shown schematically in Figure 3.1. After overnight fast, pigs 
received 30-35 mCi 18F-NaF injections through a percutaneous catheter in the 
jugular vein. Following a 90 min uptake period swine received 2.2 mg/kg of 
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xylazine (Webster Veterinary, Devens, MA) and 4.4-6.6 mg/kg of telazol (Fort 
Dodge Animal Health, Fort Dodge, IA) via intravenous injection to induce 
anesthesia. Pigs were intubated and anesthesia was maintained throughout the 
procedure by 2-4% isoflurane gas in 100% oxygen as the carrier. Heart rate, 
electrocardiogram (ECG), aortic blood pressure, blood oxygen saturation and 
respiratory rate were consistently monitored. To control the heart rate, lidocaine 
was infused (60μg/kg/min) intravenously. Pigs were transferred to a Siemens 
Biograph64 PET/CT system to begin the dual phase ECG-gated Dynamic 
Contrast Enhanced (DCE) CT and ECG-gated 18F-NaF PET scanning. A 
representative time course of the scanning protocol as well as PET, CT, and 
hybrid images are displayed in Figure 3.1, where the total 18F-NaF uptake time 
was 120 min.  
Coronary tracking (Fig. 3.2) was performed by tracing individual arteries 
along the vessel mid-line, followed by planar re-curve analysis on DCE CT 
images (31) and CAC scores were obtained using the Agatston scoring system. 
DCE CT and PET images were coregistered across gates using Analyze 11.0 
(AnalyzeDirect, Inc.), employing normalized entropy methods of Studholme 
(104), and semi-automated coronary segmentation of the left anterior descending 
(LAD) artery and right coronary artery (RCA) were performed on end diastolic 
contrast enhanced CT images and then applied to coregistered PET images for 
quantification. Due to a significant discrepancy in body weight between the two 
groups (p<0.05, n=14), data were expressed as percent injected dose (%ID/g) 
according to: 
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%𝐼𝐼/𝑔 (𝑛, 𝑖) =   𝑅(𝑛, 𝑖)
𝐼(𝑛) ∗ 100 
Where, R, D, n, and i are the coronary region in Bq/ml, decay corrected injected 
dose in Bq, subject number, and region index (LAD or RCA) respectively.   
Concurrently, 18F-NaF cardiac uptake was measured by a Global 
Molecular Calcium Score (GMCS) technique as previously described (36). Two 
experienced readers analyzed PET scans in a blinded manner using advanced 
PET/CT review software (Extended Brilliance Workstation, Philips Healthcare, 
Bothell, WA) by manually drawing regions of interest on each PET/CT image 
around the heart on transverse slices from base to the apex and corresponding 
average NaF uptake and volume of each slice was calculated and recorded (Fig. 
3.4A). Global Molecular Calcification Score (GMCS) was calculated by 
multiplying each slice volume by the average NaF generated from same ROI and 
summing the resulting numbers among the entire set of ROI analyzed. After 
scanning, animals were transported to their individual pens for decay of 
radioactive material before the next day’s interventional cardiology procedure. 
 
Intravascular Ultrasound 
Following the same anesthesia methods described above, pigs (n=15) 
were transported to the cardiac catheterization lab for IVUS imaging of the LAD 
and RCA. Methods were almost identical to those previously described in detail 
(21;40;42;44), except that the Volcano CORE instrument and 40 MHz IVUS 
catheter were used.  
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IVUS pullback images were obtained offline (Volcano DICOM Viewer 
v4.98) at 1 mm intervals for the proximal 15 mm of each coronary artery. Using 
ImageJ software (NIH), percent plaque burden measures were obtained. The 
initial lumen (IL) was traced around the elastic lamina. The actual lumen (AL) 
was traced just inside the intimal layer of the vessel wall. Using the equation (IL-
AL)/IL x 100, plaque burden were quantified for every 1 mm of the proximal 15 
mm in the two coronaries.  
 Concurrently, a secondary measure of CAD was performed to quantify 
percent wall coverage over the entire length of the artery as previously published 
(40;42;44). Our laboratory has used wall coverage analysis to quantify CAD in 
pigs with early stage atherosclerosis, prior to the stage of clinical significance.  
 
HCl Ca extraction  
To address whether or not GMCS quantification of 18F-NaF uptake in the 
heart was measuring calcium in the ventricles, HCl extraction assays were 
performed on left ventricular specimens flash-frozen in liquid nitrogen 
immediately upon excision of the heart. Total calcium was measured from a 1 
cm3 left ventricle specimen from each pig. This biochemical assessment was 
performed as previously described by Chen et al. (105).  
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Coronary & myocardial histopathology  
RCA samples from the proximal 1.5 cm were fixed in formalin before being 
embedded in paraffin blocks. 2-3 slices per artery were obtained for staining with 
hematoxylin and eosin (H&E) and von Kossa (43).  
Left ventricular specimens were also fixed and embedded prior to staining. 
Von Kossa mineral stain and Masson’s trichrome collagen stain were used to 
assess the myocardium and microvasculature.  
 
Statistics  
Data are described as mean ± 1 SEM, where p<0.05 was considered 
statistically significant. One-tailed Student’s t-test, one-way ANOVA with Student-
Newman-Keuls post-hoc test, and Pearson’s correlation were used in PRISM 
software (GraphPad, San Diego, CA).  
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Results 
Metabolic data  
Pigs on the atherogenic diet developed MetS, as indicated by the risk 
factors of increased bodyweight, total cholesterol, triglycerides, and diastolic 
blood pressure (Table 3.1). Measures were significantly increased compared to 
age- and gender-matched lean pigs.  
 
18F-NaF PET/CT imaging  
All pigs, lean and MetS, revealed no significant evidence of CAC by CT 
with Agatston calcium scores of 0. Simultaneous PET imaging revealed almost a 
2.5-fold increase of 18F-NaF uptake in the hearts of MetS pigs compared to lean 
(351 ± 17 vs 145 ± 26, p<0.05) by the GMCS technique (Fig. 3.3A&B). These 
data significantly correlated with percent plaque burden in both the LAD (p<0.05, 
r=0.78) and RCA (p<0.05, r=0.86) from all pigs (Fig. 3.3C&D).  
DCE CT and coronary tracking allowed for direct measures of 18F-NaF 
uptake in the LAD and RCA arteries.  Using %ID/g as a discrete regional 
measure of uptake, significantly more 18F-NaF uptake was measured in the 
proximal region of both LAD and RCA of MetS pigs compared to lean (LAD: 0.95 
± 0.11 %ID/g vs 0.51 ± 0.05 %ID/g, p<0.05; RCA: 0.98 ± 0.11 %ID/g vs. 0.54 ± 
0.03 %ID/g, p<0.05) (Fig. 4A & 4C). In the LAD of lean and MetS pigs, 18F-NaF 
showed a weak correlation with plaque burden measures in the same region of 
the artery (p=0.08, r= 0.48) (Fig. 3.4C).  However, in the RCA of all pigs, this 
correlation between microcalcification measured by 18F-NaF uptake and state of 
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CAD measured by the IVUS plaque burden measure was strong (p<0.05, r= 
0.87) (Fig. 3.4D). 
 
IVUS plaque burden  
In Figure 3.5, images from coronary pullbacks in the proximal 15 mm of 
the artery show the lack of atherosclerotic plaque burden in lean pigs (Fig. 3.5A, 
LAD: 1 ± 0%, RCA: 0.2 ± 0%) compared to an early stage of CAD in MetS pigs 
with plaque burden development (Fig. 3.5B, LAD: 25 ± 1%, p<0.05, RCA: 20 ± 
0%, p<0.05), ~25-fold greater than Lean (Fig. 3.5C). Of the MetS pigs with CAD, 
only one pig showed evidence of CAC by IVUS (Fig. 3.5D). The ~15% wall 
coverage by calcification in Figure 3D contrasted with the complete absence of 
even early stage intimal thickening in the other ~85% of this arterial cross-section 
shows the heterogeneity of the CAC process.  
 
Left ventricle HCl Ca extraction and histopathology  
Biochemical assessment revealed no significant difference in total calcium 
in the left ventricle from lean (1.11 ± 0.05 μmol/g) and MetS pigs (1.17 ± 0.06 
μmol.g) (p=0.24) (Fig. 3.6A&B).   
Von Kossa mineral staining of LV specimens from lean and MetS pigs 
revealed no evidence of myocardial or microvascular calcification in either group 
(Fig. 3.6C). Masson’s trichrome stains were used for structural comparison and 
assessment of myocardial collagen deposition (Fig. 3.6D).  
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Right coronary artery histopathology  
H&E (Fig. 3.7A) and von Kossa (Fig. 3.7B) staining of proximal RCA 
specimens were positive for 45% of MetS pigs (n=11).  
 
IVUS wall coverage analysis  
The percent wall coverage IVUS measure of the entire artery was more 
variable compared to the percent plaque burden data. As shown in Figure 3.8A, 
a pig with early CAD, and therefore a low percent plaque burden, has concentric 
wall coverage and a high probability of heighted cellular activity during that 
evolving stage of CAD. Wall coverage was measured for every 1 mm of the 
entire LAD in lean and MetS pigs. As expected, MetS pigs had ~14-fold greater 
intimal thickening compared to the leans (51 ± 6% vs. 3 ± 1%, p<0.05) (Fig. 
3.8B). When compared to 18F-NaF %ID/g in the LAD of each pig, the wall 
coverage data significantly correlated with microcalcification activity measured by 
PET (p<0.05, r=0.67)) (Fig. 3.8C).  
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Discussion 
 Clinically the use of CT CAC has been standardized and currently serves 
as the non-invasive gold standard for evaluating plaque burden. Based on the 
current work and the relevant literature suggesting that microcalcifications are 
present in early plaques, the question then remains, if these microcalcifications 
are too small to be measured by CT CAC scoring, why focus on this measure for 
clinical diagnosis of cardiovascular risk? Detrano et al. found CT CAC scoring is 
not more effective than risk-factor information and is not an accurate predictor in 
these asymptomatic patients with early CAD (106). Also, McEvoy et al. make the 
key point in their state-of-the-art review that CAC progression is an essential 
clinical measure, rather than a patient’s CAC score alone (32). This requires 
multiple CT scans per patient to observe changes in plaque structure and 
severity. However, a single PET/CT scan may reveal current molecular activity 
and mineral metabolism, which is well-established to indicate plaque 
progression.  
CAD is a highly complex disease progressing through stages of 
inflammation, lipid accumulation, calcium deposition, thrombosis, and finally 
fibrosis. CAC is classically observed in the vicinity of lipid-rich regions within 
atherosclerotic plaques in close proximity to inflammatory cells (107). The 
earliest form of calcium deposits in the coronary vasculature has been observed 
in type IV lesions from histological studies (26). A type IV lesion characterization 
involves plaque that is lipid laden, but not yet containing thick layers of fibrous 
connective tissue and are not yet largely calcified (type V) (43;88). These non-
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calcified or micro-calcified lipid-rich plaques are the most vulnerable for plaque 
rupture (10), however, these type IV lesions can return a CAC score of 0 from CT 
imaging (32). In the current work, we have extended the concept of CAC by 
showing in an outstanding preclinical swine model of CAD (40;42-45) that 18F-
NaF PET-CT can detect CAC in type I, II, and III lesions.  
Cocker et al. (108) corroborate the viewpoint that monitoring CAD time 
course with multiple imaging modalities (18F-FDG, 18F-NaF, and CT) is important 
to better understand the progression of CAC. Several groups have identified 18F-
FDG as an indicator of CAD progression by inflammation and macrophage 
activity (109-112). However, recently it has not proven to be reliable for detection 
of high-risk plaque (38). The major limitation of this tracer is its high uptake in the 
myocardium due to high metabolic activity, thus leading to a low target to 
background ratio when measuring in the coronaries. By contrast, 18F-NaF has 
limited myocardial and blood uptake yielding very high target to background 
ratios. Therefore, of the available commercial tracers 18F-NaF may provide the 
best opportunity for detection of early CAD/CAC progression.  
In this preclinical PET/CT study, we have demonstrated that increased 
18F-NaF uptake in the coronaries can detect early calcium metabolism in pigs 
with CAD that lack frank evidence of calcification by both IVUS and CT imaging. 
These findings render the interpretation that 18F-NaF binds to microcalcifications 
that are on a molecular level which is too small to be detected using standard 
clinical imaging modalities. Evidence for this conclusion lies within our 
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histopathology data revealing the presence of microcalcifications within the 
proximal region of the RCA, which were only detected by 18F-NaF PET imaging. 
Because wall coverage is a quantitative analysis of early CAD, i.e. type I, 
II, and III lesions composed of fatty streaks and intimal thickening, our data 
correlate superbly with 18F-NaF uptake because it is indicating early, active 
mineral metabolism. This evidence for early phase CAC in type I, II, and III 
lesions is unprecedented in human clinical medicine or preclinical animal studies. 
Nonetheless, the evidence is consistent with substantial data showing 
dysfunctional intracellular calcium signaling in coronary smooth muscle in 
diabetic dyslipidemia and metabolic syndrome reviewed recently (46). It is 
reasonable to propose that dysfunctional smooth muscle calcium signaling leads 
to extracellular microcalcification that is detected by 18F-NaF uptake into the wall. 
Mechanistically, the overloaded CSM calcium stores and/or cytosol would 
enhance matrix vesicles formation providing the target for 18F-NaF, similar to the 
calcium-dependent mechanism proposed by Kapustin et al. for the role of 
smooth-derived matrix vesicles in vascular microcalcification when calcium 
homeostasis is lost (113). This mechanism has been shown to be exacerbated in 
inflammation by macrophage-derived matrix vesicles (114). Electron micrographs 
showing numerous vesicles / caveolae at the sarcolemma of coronary smooth 
muscle are consistent with the notion of matrix vesicle formation (115). These 
vesicles have been observed in athero-prone areas of the human aorta (116) and 
in fibrous caps of vulnerable plaque (117).  
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It is also important to note that our colleagues Wastney et al., have 
previously used 41Ca kinetic modeling to show increased rate of calcium 
deposition into the coronary tissue of MetS Ossabaw compared to lean (118). 
The increase in 18F-NaF uptake in MetS Ossabaw coronaries found in this 
current study corroborate with their previous findings.  
 
Study limitations  
Documentation of progression of CAC from 18F-NaF whole artery uptake 
and global molecular calcification by longitudinal measures in the same pig as 
CAD/CAC progressed to IVUS, histopathological, and CT resolvable CAC would 
have strengthened the study.  
 
Conclusions   
We have shown in a preclinical swine model of CAD (40;42-45) that 18F-
NaF PET-CT can detect CAC in early atherosclerotic lesions, thereby extending 
the concept of CAC to significantly earlier in the pathogenesis of CAD. The data 
also argue for more widespread use of 18F-NaF measures of CAC in humans.  
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Figure & Tables 
 
Figure 3.1. Ossabaw swine underwent simultaneous PET/CT cardiac 
imaging. A. Timeline for PET/CT protocol. After 18F-NaF injection (blue arrow, -
90 min), pigs were transferred to the scan room (red arrows, 0-30 min). PET 
imaging (red dots, 30-90 min) began 120 mins post tracer injection. Non contrast 
CT (green arrows, 0-20 min), contrast injection (IsoVue, blue arrow, 25 min), and 
DCE CT imaging (green dots, 25-60 min) followed. B. High spatial resolution in 
CT image allows for identification of anatomical structures. C. PET image reveals 
high 18F-NaF uptake in the bones of the Ossabaw. D. Hybrid image of co-
registered PET and CT images after intravenous contrast injection. PET= 
positron emission tomography; CT= computed tomography; DCE= dynamic 
contrast enhanced; R= right; A= anterior; L= left; P=posterior; Tr= trachea; PA= 
pulmonary artery; Ao= aorta; LV= left ventricle.   
 
Figure 3.2. Dynamic contrast enhanced (DCE) Coronary Tracking. A. From 
DCE CT images, the artery was identified for every transverse slice through the 
heart. B. A 3-D reconstruction of the heart shows the path of the LAD (red line). 
C. Images were reformatted along the linear axis of the artery. PET images were 
co-registered to these images in order to measure tracer uptake in the 
coronaries. RV= right ventricle; LV= left ventricle; LAD= left anterior descending; 
other abbreviations are the same as Figure 3.1. 
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Figure 3.3. Global Molecular Calcification Score (GMCS). A. A region of 
interest was drawn around the heart on each transverse CT slice image. Using 
co-registered PET images, 18F-NaF uptake was quantified and a GMCS was 
calculated for the entire heart using a previously described method (36). B. MetS 
pigs (n=11) had almost a 2.5-fold higher GMCS compared to lean pigs (n=2) 
(p<0.05). C. GMCS significantly correlates with LAD plaque burden (n=13, 
p<0.05). D. GMCS significantly correlates with RCA plaque burden (n=9, 
p<0.05). Abbreviations are the same as Figures 3.1-3. 
 
Figure 3.4. Percent injected dose (%ID) per gram body weight (g) in the 
proximal coronary arteries. A. MetS pigs (n=11) had increased 18F-NaF %ID/g 
in the LAD compared to lean (n=3) (p<0.05). B. Pearson’s Product correlation 
revealed a trend towards a positive %ID/g and plaque burden relationship (n=13, 
p<0.05). C. MetS pigs had increased 18F-NaF %ID/g in the RCA compared to 
lean (p<0.05). D. There was a significant correlation between RCA %ID/g and 
plaque burden (n=10,p<0.05). Abbreviations are the same as Figures 3.2-3. 
 
Figure 3.5. Intravascular ultrasound (IVUS) imaging and quantification of 
coronary artery disease (CAD). A. Cross sectional view of lean Ossabaw 
coronary with vascular wall traced in red. B. MetS pigs with CAD; initial lumen 
(IL) or elastic lamina is traced in red; actual lumen (AL) traced in yellow; percent 
plaque burden = (IL-AL)/ILx100. C. MetS Ossabaw (n=11) had significantly 
greater CAD compared to lean (n=4) by plaque burden quantification in the 
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proximal 15 mm of the LAD (p<0.05) and RCA (p<0.05). D. One pig showed 
evidence of local, spotty calcification by IVUS (green arrow points to lesion, 
green dashed line outline acoustic shadowing effect). MetS= metabolic 
syndrome; CAD= coronary artery disease; RCA= right coronary artery; IVUS= 
intravascular ultrasound; other abbreviations are the same as Figure 3.2. 
Distance between dots is 1 mm.  
 
Figure 3.6. Left ventricular total calcium. A. Specimen was collected from LV 
away from any conduit artery (yellow box). B. There was no difference in LV total 
calcium between lean (n=6) and MetS pigs (n=11). C. Histopathology of LV 
revealed no evidence of myocardial or microvasculature calcification in lean 
(n=6) and MetS pigs (n=11) with von Kossa mineral staining (mineral= black 
sediment). D. Masson’s trichrome staining shows healthy, non-fibrotic 
myocardium. LV= left ventricle; abbreviations are the same as Figure 3.3. 
 
Figure 3.7. Coronary histopathology revealed microcalcifications. A. A 
representative image of an H&E-stained proximal RCA wall from a MetS pig 
revealing evidence for atherosclerotic CAC (black arrows). B. A representative 
image of an von Kossa-stained proximal RCA wall from a MetS pig revealing 
evidence for atherosclerotic CAC (black arrows).  CAC was observed in 45% of 
MetS pigs.  
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Figure 3.8. Early stage CAD was quantified as percent wall coverage using 
IVUS images. A. Example of a MetS pig with 100% wall coverage (concentric 
fatty streak, intimal thickening) and 25% plaque burden, which is not clinically 
significant. B. MetS pigs (n=10) had ~16-fold greater percent wall coverage 
compared to lean pigs (n=3) (p<0.05). C. Wall coverage quantification 
significantly correlated with %ID/g (p<0.05). Abbreviations are the same as 
Figures 3.3 & 5. Distance between dots is 1 mm.  
  
81 
 
Figure 3.1. 
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Figure 3.2.  
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Figure 3.3. 
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Figure 3.4.  
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Figure 3.5. 
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Figure 3.6.  
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Figure 3.7.  
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Figure 3.8.  
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Table 3.1. Metabolic Characteristics of Ossabaw miniature swine.  
 Lean (n=13) Mean ± SEM 
MetS (n=11) 
Mean ± SEM 
Body Weight 
(kg) 70.7 ± 1.9 96.8 ± 4.3* 
Fasting Blood Glucose 
(mg/dL) 62.2 ± 2.8 61.5 ± 3.3 
Total Cholesterol 
(mg/dL) 57.6 ± 2.8 590.0 ± 45.5* 
Triglycerides 
(mg/dL) 28.1 ± 4.3 110.4 ± 25.3* 
Systolic Blood Pressure 
(mmHg) 128.3 ± 2.7 138.5 ± 5.6 
Diastolic Blood Pressure 
(mmHg) 74.4 ± 3.9 97.1 ± 7.1* 
One-tailed Student’s t-test was performed to compare lean and MetS 
characteristics for each metabolic data set.   
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Abstract 
Alterations in coronary smooth muscle (CSM) Ca2+ regulation were studied in the 
Ossabaw swine model of metabolic syndrome (MetS) over the time course of 
coronary artery disease (CAD) progression. MetS was induced by excess calorie 
atherogenic diet for 6, 9, or 12+ months and compared to lean controls on normal 
standard diet. Isometric tension studies on isolated coronary arteries revealed 
that 9 months of MetS increased tension development to K depolarization vs. 6 
months and lean controls, whereas at 12 months tension was significantly 
reduced. MetS increases CAD and CSM Ca2+ dysregulation. CSM were isolated 
enzymatically and imaged with the fluorescent Ca2+ indicator fura-2. There was 
no difference in basal Ca2+ levels between all groups. We released sarcoplasmic 
reticulum (SR) Ca2+ stores maximally with caffeine. The peak Ca2+ transient, 
which largely represents the caffeine-sensitive SR Ca2+ store capacity, was 
increased at 9 months and decreased at 12 months MetS vs. lean. There was no 
difference at 6 months.  After the SR store depletion, a sustained Ca2+ signal 
above basal levels remained in the 9 month MetS group, reflecting store-
operated Ca2+ entry as well as decreased Ca2+ extrusion ability. Intravascular 
ultrasound (IVUS) showed greater atherosclerosis correlates with length of 
atherogenic diet. Coronary artery calcification (CAC) was observed on IVUS in 
pigs fed for 12+ months with “late stage” CAD. In an organ culture model of CAC, 
nifedipine failed to inhibit induction of CAC, suggesting voltage-gated Ca2+ 
channels are not involved in CSM Ca2+ overload. Collectively, these data suggest 
that CSM undergo dedifferentiation from a contractile to a synthetic phenotype 
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defined by CSM proliferation and migration and increased intracellular Ca2+ 
signaling in “early stage” CAD. As CAD further progresses to “late stage”, CSM 
dedifferentiate to an osteogenic phenotype with decreased intracellular Ca2+ 
signaling and increased extracellular calcification.  
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Background 
The latest report from the Centers for Disease Control and Prevention 
revealed that more than one-third of American adults are obese (1).  While the 
American sedentary lifestyle undoubtedly plays a role in this epidemic, the homo 
sapiens’ “thrifty genotype” is also contributing to the cause. This “thrifty 
genotype”, first described in a classical report by Neel (2), is synonymous to a 
propensity to obesity. In his recent review, O’Rourke labeled modern day’s 
overabundance of food and a lack of energy-intensive labor, both of which are 
fueling this American obesity epidemic, as an “obesogenic” environment (3). 
This “obesogenic” environment has fueled a parallel catastrophic 
diagnosis for Americans – the metabolic syndrome (MetS), which is a 
combination of 3 or more of the following risk factors associated with metabolic 
abnormalities: central obesity, dyslipidemia, hypertension, impaired glucose 
tolerance, and insulin resistance (119). When an individual presents with multiple 
MetS risk factors, their chances for adverse or even fatal cardiovascular 
problems are far greater than if presenting one risk factor alone (6). 
Together, obesity and MetS are fueling the number 1 killer of Americans, 
coronary artery disease (CAD). CAD progresses through a spectrum of stages 
(26;43) beginning with early clinically insignificant neointimal thickening due to 
lipid deposition in the arterial wall.  Progression continues with further neointimal 
thickening due to further lipid deposition and inflammatory factors infiltrating the 
area (48;49). The coronary smooth muscle (CSM)-rich medial layer of the wall 
will also begin to thicken due to a shift in CSM phenotype from the differentiated, 
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contractile state (cCSM) found in healthy arterial walls to a dedifferentiated, 
synthetic phenotype (sCSM) known to proliferate and migrate in towards the 
coronary lumen. sCSM, most specifically recognized by the loss of smooth 
muscle myosin heavy chain (SM-MHC) (120),  are also secretory cells that after 
further proliferation and migration into the neointimal lesion will enhance fibrosis 
and plaque complexity. A third more recently recognized phenotype of CSM is a 
dedifferentiated osteogenic cell (oCSM), which expresses bone-like genes (i.e., 
RUNX2) (30;51) and releases matrix vesicles (30;121) into the extracellular 
matrix leading to calcification within advanced CAD lesions.  
 Being a ubiquitous intracellular messenger, Ca2+ can signal CSM 
contraction, proliferation, migration, and gene transcription. It is imperative that 
CSM tightly regulate Ca2+ using various Ca2+ transporters (Fig. 4.1A). to 
compensate for changes in the local environment, specifically in a MetS milieu.  
Several reports have described changes in intracellular CSM Ca2+ signaling in 
health vs. disease and these characteristics of Ca2+ handling strongly influence 
the phenotypic state of the cell (50).  
 We cannot define just two divisions of CSM Ca2+ “health”: before CAD 
onset vs. after CAD onset. The plasticity of CSM is much more complex than 
this, and more studies should observe the time course of intracellular CSM 
changes in correlation with the severity of CAD when interpreting the data. Here 
we utilize the Ossabaw miniature swine model of MetS and CAD (39-44) to study 
the changes in CSM Ca2+ signaling over a time course of CAD progression from 
healthy, lean pigs to obese, MetS pigs with advanced calcified CAD lesions.  
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Methods 
Animal Care 
Six month old Ossabaw miniature swine were fed 1 kg of an excess-
calorie atherogenic diet (KT-324, Purina Test Diet, Richmond, IN; 16% kcal from 
protein, 41% kcal from complex carbohydrates, 19% kcal from fructose, and 
43% kcal from fat) daily for 6 (n=6), 9 (n=7), or 12+(n=9) months. The feed was 
supplemented with cholesterol (2.0%), hydrogenated coconut oil (4.70%), 
hydrogenated soybean oil (8.40%), cholate (0.70%), and high fructose corn syrup 
(5.0%) by weight resulting in the induction of metabolic syndrome (MetS) and 
CAD (40;42-45). Lean control pigs (n=9) were fed 725 g of a standard diet (5L80, 
Purina Test Diet, Richmond, IN; 18% kcal from protein, 71% kcal from complex 
carbohydrates, and 11% kcal from fat). Animals were kept in individual housing 
with free access to drinking water and on a 12-hour light/dark cycle. This protocol 
was approved by the Indiana University School of Medicine Animal Care and Use 
Committee.  
 
Intravascular Ultrasound (IVUS) for quantification of coronary artery 
disease 
After an overnight fast, pigs received 2.2 mg/kg of xylazine (Webster 
Veterinary, Devens, MA) and 5.5 mg/kg of telazol (Fort Dodge Animal Health, 
Fort Dodge, IA) via intramuscular injection to induce anesthesia. Anesthesia was 
maintained throughout the procedure by 2-4% isoflurane gas in 100% oxygen as 
the carrier. Heart rate, the electrocardiogram (ECG), aortic blood pressure, blood 
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oxygen saturation, and respiratory rate were consistently monitored. 
Intravascular ultrasound (IVUS) imaging was performed on the left anterior 
descending (LAD) artery. Methods were similar to those previously described in 
detail (21;40;42;44).  
Still frame IVUS pullback images were obtained offline at 1 mm intervals 
(Fig. 4.2A-C). Percent plaque burden measures were obtained using Image J 
software (NIH). The initial lumen (IL) was traced around the elastic lamina. The 
actual lumen (AL) was traced just inside the intimal layer of the vessel wall. Using 
the equation (IL-AL)/IL x 100, plaque burden was quantified for every 1 mm of 
the LAD. Quantification of % wall coverage over the entire length of the artery 
was performed as previously published (40;42;44). Our laboratory has used wall 
coverage analysis to quantify CAD in pigs with early stage atherosclerosis 
characterized by fatty streaks, and intermediate lesions (Type II, III) prior to later 
stages with more fibrous and complex lesions (Type IV-VI) (43;122).  
 
Isometric tension studies for functional assessment of fresh and cultured 
coronary rings 
Coronary rings (2-4 mm) were hung on pressure transducers in 37°C  
water-jacketed organ baths with a Ca2+-containing Krebs solution (in mM: 131.5 
NaCl, 5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 25 NaHCO3, 10 glucose, 4 CaCl2). 
Optimal length was measured by contractions of isolated arteries to 60 mM KCl 
and passive tension was increased in gram increments until there was <10% 
change in active tension development to 60 mM KCl (typically equaled ~4 g) as 
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previously described (59;75;123). Once the arteries stabilized they were 
contracted with 10, 20, and 80 mM KCl and tension development was measured.  
 
Fluorescent imaging for assessment of CSM intracellular Ca2+ signaling 
from freshly harvested and cultured coronary rings 
Because vasoconstriction and CSM contraction are a result of increased 
Ca2+, we wanted to directly compare tension development data to intracellular 
Ca2+ signaling. Ossabaw swine CSM were enzymatically isolated from freshly 
dissected coronary rings and loaded with 2.5 μM fura-2 AM (Molecular Probes, 
Life Technologies, Eugene, OR) as previously described (42;44;53;124). Fura-2 
loaded cells were switched to a 2 mM Ca2+ physiologic salt solution (PSS), (in 
mM: 138 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, titrated to a pH 
of 7.4 with NaOH) and kept on ice before being placed on a coverslip contained 
within a constant-flow superfusion chamber that was mounted on an inverted 
epifluorescence microscope (model TMS-F, Nikon). Whole-cell intracellular Ca2+ 
levels were measured at room temperature (22 to 25°C) using the InCa++ 
Imaging System (Intracellular Imaging, Cincinnati, OH). Loaded CSM were 
depolarized with 80 mM K+ (80K) (in mM: 2 CaCl2, 63 NaCl2, 1 MgCl2, 80 KCl, 
10 HEPES, 10 glucose, titrated to a pH of 7.4 with NaOH) to initiate Ca2+ influx 
through voltage-gated Ca2+ channels (VGCC), stimulated with 5 mM caffeine 
(5CAF) to measure Ca2+ release from the sarcoplasmic reticulum (SR), and 
assessed for Ca2+ buffering ability/store-operated Ca2+ influx after the caffeine-
induced elevation in cytosolic Ca2+ level (Fig. 4.1B). 
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In a second protocol, CSM from organ cultured domestic swine coronary 
rings (see methods below) were exposed to the same protocol, followed 
immediately by a 2 mM Ba2+ depolarizing solution (2Ba80K5Na) (in mM: 2 BaCl2, 
63 LiCl, 1 MgCl2, 80 KCl, 10 mM HEPES, 10 mM glucose, titrated to a pH of 7.4 
with NaOH) (Fig. 4.7A) . This solution contains low Na+, which will inhibit NX and 
the 80 mM K will activate VGCC, which are highly permeable to Ba2+. Barium 
was a good tool because it binds fura-2, but cannot be rapidly extruded by the 
inhibited NX and cannot be transported by Ca2+ pumps (125;126), allowing for a 
more pure measure of Ba (divalent cation) influx. Previously, exposure of the 
2Ba80K5Na-activated cells to nifedipine, the VGCC inhibitor, confirmed 
activation of VGCC is inducing divalent cation (Ba / Ca) influx into the cell (125).  
 
Sterile isolation of porcine coronary rings 
Domestic farm pigs were anesthetized with telazol/ketamine/xylazine (1 
mL/ 50 lb) and then euthanized by pentobarbital (1 mL/ 10 lb). Excision of the 
heart was performed with sterile gloves and tools. The heart was removed with 
the pericardial sac intact to help maintain sterility. In a sterile field, the pericardial 
sac was removed and the heart was rinsed with sterile-filtered PSS  plus 1% 
penicillin streptomycin (PS) (Gemini Bio-products, Sacramento, CA). Gross 
dissection of coronary conduit arteries occurred immediately after removal of the 
heart and specimens were placed in ice-cold sterile-filtered PSS + 1% PS. The 
tissue was transported to the sterile hood for fine dissection. Arteries were 
trimmed of adventitia, cardiac and adipose tissues.  
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Coronary ring organ culture 
To induce an advanced stage of in vitro CAD/CAC, domestic pig coronary 
rings were cultured in 12-well plates at 37°C with 4.6% CO2 in a base media of 
normal glucose (100 mg/dL) DMEM (Sigma-Aldrich, St. Louis, MO) + 1% PS. 
After dissection, rings were randomly assigned to one of 4 groups: freshly 
harvested, control, calcification (CA), or calcification + nifedipine (NIF). Control 
rings were cultured in the base media alone. CA rings were cultured in the base 
media supplemented with 3.8 mM sodium phosphate and 7.5 U/mL alkaline 
phosphatase enzyme (Promega, Madison, WI) to induce CAC within the vascular 
wall. This CA media recipe has previously induced medial calcification in rat 
aortic ring cultures (127). NIF rings were cultured in base media supplemented 
with the CA media plus the specific VGCC inhibitor, nifedipine (1 μM; Santa Cruz 
Biotechnology, Santa Cruz, CA). Rings were cultured for 4 and 7 days. Fresh 
rings were also used for Day 0 measures (freshly harvested). 
 
Coronary ring histopathology 
Cultured rings were formalin-fixed for at least 24 hours. Samples were 
then transferred to plastic cassettes and placed in 70% ethanol. After paraffin 
embedding and slicing, slides were stained with Von Kossa mineral stain to 
assess calcification within the coronary wall and Masson’s trichrome to assess 
collagen deposition as a measure of in vitro CAD progression. Analysis was 
performed using ImageJ software (NIH) similar to a previous method (128).  
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Statistics 
 Data are described as mean ± SEM with p<0.05 considered statistically 
significant. One-way analysis of variance (ANOVA) and two-way ANOVA with 
Student-Newman-Keuls (SNK) post hoc test were used in PRISM software 
(GraphPad, San Diego, CA).   
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Results 
Metabolic characteristics of Ossabaw swine  
 Pigs on the atherogenic diet developed MetS as indicated by the risk 
factors in Table 1. Body weight, systolic blood pressure, diastolic blood pressure, 
total cholesterol, and triglyceride measures were increased in MetS compared to 
lean pigs. 
 
Quantification of coronary artery disease (CAD) progression 
 Coronary artery plaque burden increased in MetS pigs with time on 
atherogenic diet (Fig. 4.2D), but did not significantly increase until pigs were fed 
for 12+ months (lean= 1 ± 0.2%, 6 months= 3 ± 1%, 9 months= 7 ± 2%, 12+ 
months= 21 ± 5%, p<0.05). Wall coverage, which shows mainly Type II and III 
lesions that are present in milder CAD, increased much earlier in the CAD 
progression time course (lean= 3 ± 1%, 6 months= 25 ± 7%, 6 months= 41 ± 7%, 
12+ months= 41 ± 10%, p<0.05). These data support our statement that % wall 
coverage is a strong tool for quantification of early intimal CAD prior to the stage 
of more intimal plaque. From these quantification methods we have 
characterized pigs with CAD due to 6-9 months on atherogenic diet as “early 
stage” CAD and 12+ months on atherogenic diet as “late stage” CAD. 
 
Fresh coronary ring tension development 
 Functional assessment of coronary rings from lean pigs revealed no effect 
of age on tension development to 20 mM KCl (average= 1.8 ± 0.3 g, p= 0.1) (Fig. 
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4.3A). Rings from MetS pigs revealed a biphasic change in tension development 
to 20 mM KCl as CAD progressed (6 months= 1.8 ± 0.6 g, 9 months= 5.0 ± 1.0 g, 
12 months= 0.7 ± 0.1 g, p<0.05) (Fig. 4.3B). When compared to age-matched 
leans, rings from MetS pigs with “early stage” CAD after 9 months of atherogenic 
feeding developed significantly more tension to 20 mM KCl (5.0  ± 1.0 g vs 1.4 ± 
0.3 g, p<0.05). Once coronary plaque burden significantly increases in MetS pigs 
fed atherogenic diet for 12+ months, tension development dramatically 
decreases below that of rings from lean age-matched pigs (0.7 ± 0.1 g vs. 2.8 ± 
0.4 g, p<0.05) (Fig. 4.3C).   
 
Fresh coronary smooth muscle (CSM) intracellular Ca2+ signaling 
 Intracellular imaging of CSM from varying stages of Ossabaw CAD 
progression revealed a similar biphasic pattern as seen in the functional tension 
development data. CSM from pigs with “early stage” CAD had greater Ca2+ influx 
through VGCC after activation by 80K compared to cells from age-matched lean 
pigs as quantified by area under the curve (18 ± 2 vs. 10 ± 0.1, p<0.05). CSM 
from pigs with “late stage” CAD lost this transient increase in VGCC activation 
(Fig. 4.4B). Release of the SR store with 5CAF revealed a significantly 
heightened Ca2+ transient in CSM from MetS pigs with “early stage” CAD 
compared to CSM from age-matched leans (0.41 ± 0.07 vs. 0.20 ± 0.01, p<0.05). 
Again, this increased Ca2+ signal in CSM from pigs with “early stage” CAD was 
lost in CSM from pigs with “late stage” CAD. (Fig. 4.4C). Finally, Ca2+ buffering 
impairment along with simultaneously store-operated Ca2+ influx was assessed 
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after SR store depletion. While this revealed a trend towards the same biphasic 
pattern of Ca2+ changes during the time course of CAD progression, no 
significant changes were observed (Fig. 4.4D).  
 
Induction of coronary artery calcification (CAC) by organ culture 
 Coronary wall medial thickness and collagen deposition were not 
statistically different between organ culture groups (data not shown).  Evidence 
for early coronary calcification was observed in rings from 7 days in CA and NIF 
medias (Fig. 4.5C&D), but not in fresh or control rings.  
 
Cultured ring tension development 
Control media  
Compared to freshly isolated coronary rings, rings cultured for 4 and 7 
days in the control media were functionally no different after exposure to 10, 20, 
or 80 mM KCl. However, tension development to 20 mM KCl was significantly 
increased at 7 days in culture compared to just 4 days (5.0 ± 1.4 g vs. 1.4 ± 0.3 
g, p<0.05). This trend was observed in rings cultured for 7 days compared to 
freshly isolated rings (Fig. 4.6A). 
Calcification (CA) media 
After 4 days in CA media, tension development was not different from 
fresh rings. However, after 7 days in CA media, a significant increase in tension 
development to 20 mM KCl compared to just 4 days was observed (5.3 ± 0.6 g 
vs. 2.3 ± 0.5 g, p<0.05). When comparing functional assessment of freshly 
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isolated coronary rings to rings cultured in CA media for 7 days, a significant 
increase in cultured ring tension development was observed from 20 mM KCl 
(5.3 ± 0.6 g vs. 2.8 ± 0.6 g, p<0.05) and 80 mM KCl (8.1 ± 0.8 g vs. 6.3 ± 0.7 g, 
p<0.05) stimulation (Fig. 4.6B).   
Calcification + Nifedipine (NIF) media 
 After 4 days of culture in NIF media, tension development was severely 
blunted to both 20 mM KCl (0.4 ± 0.1 g vs. 2.8 ± 0.8 g, p<0.05) and 80 mM KCl 
(1.1 ± 0.3 g vs. 6.3 ± 0.7 g, p<0.05) compared to freshly isolated rings. After 7 
days in culture, tension development to 80 mM KCl was still severely blunted 
compared to freshly isolated rings (1.7 ± 0.4 g vs. 6.3 ± 0.7 g, p<0.05) while 
tension development to 20 mM KCl recovered to be functionally no different. 
When comparing 4 and 7 days of organ culture in NIF media, there was no 
functional difference between tension development to 10, 20, or 80 mM KCl (Fig. 
4.6C).   
Tension development to 20 mM KCl after 7 days in organ culture 
  After 7 days of culture in NIF media, tension development to 20 mM KCl 
was blunted compared to rings cultured in both CA media (5.3 ± 0.6 g vs. 1.5 ± 
0.3 g, p<0.05) and control media (5.0 ± 1.34 g vs. 1.5 ± 0.3 g, p<0.05) (Fig. 
4.6D). There was no significant difference between overall tension developments 
of rings in control media compared to CA media.  
Tension development to 80 mM KCl after 7 days in organ culture 
 After the first 4 days of culture in NIF media, tension development to 80 
mM KCl was blunted compared to rings cultured in both CA media (8.3 ± 0.9 g 
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vs. 1.1 ± 0.3 g, p<0.05) and cotnrol media (5.7 ± 1.0 g vs. 1.1 ± 0.3 g, p<0.05). 
After 7 days of culture in NIF media, tension development to 80 mM KCl was still 
blunted compared to rings cultured in CA media (8.1 ± 0.8 g vs. 1.7 ± 0.4 g, 
p<0.05) and control media (6.6 ± 1.6 g vs. 1.7 ± 0.4 g, p<0.05) (Fig. 4.6E). There 
was no significant difference between overall tension developments of rings in 
control media compared to CA media. 
 
Cultured ring CSM intracellular Ca2+ signaling 
 Independent of time in culture and media, no difference was observed in 
CSM baseline Ca2+ levels (Fig. 4.7B). Fresh CSM had significantly greater 
caffeine-sensitive Ca2+ release compared to all CSM from all cultures (p<0.05). 
While no statistical difference was revealed among CSM from cultured rings, a 
trend of decreased SR Ca2+ store is seen in CSM from 4 and 7 days in CA media 
compared to both control and NIF (Fig. 4.7C). Finally, rate of Ba2+ influx was 
assessed as a pure influx measure during 2Ba80K5Na exposure. No difference 
was seen between any of the CSM groups (Fig. 4.7D).  
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Discussion 
Several association studies have been conducted correlating CSM Ca2+ 
regulation and transporter expression in CAD (for review (46)). However, it is 
important to acknowledge at which stage of CAD progression these changes 
occur. From the IVUS imaging, we classified two stages of CAD in these study 
pigs: “early stage” CAD (0-9 months on atherogenic diet) and “late stage” CAD 
(>9 months on atherogenic diet). The clear distinction between the two stages of 
disease is the shift from neointimal wall coverage to the significant increase in 
plaque burden observed in the pigs fed the atherogenic diet for 12+ months.  
  Previous studies in freshly isolated porcine CSM have demonstrated that 
impairment of Ca2+ extrusion mechanisms may be the initial deficiency in Ca2+ 
handling (52). These Ca2+ extrusion impairments include a decrease in the 
plasma membrane Ca2+ ATPase (PMCA) function and a loss of the physical 
coupling of intracellular Ca2+ store release and Ca2+ extrusion at the plasma 
membrane by both PMCA and Na+-Ca2+ exchanger (NX) (52). This decrease in 
CSM Ca2+ extrusion efficiency could explain the trend towards a  sustained Ca2+ 
transient observed after caffeine exposure in CSM from MetS Ossabaw with 
“early stage” CAD (Fig. 4.4D). Consequently, if CSM are not able to buffer Ca2+ 
as levels increase in the cytosol, this would lead to increased CSM contraction 
due to sustained Ca2+ levels, which was observed in coronary rings subjected to 
isometric tension studies. Rings isolated from pigs with “early stage” CAD 
revealed increased tension development to 20 mM KCl, a characteristic that was 
lost in coronary rings from pigs with “late stage” CAD (Fig. 4.3C).  
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 Ca2+ can be buffered from the cytosol in two manners: plasma membrane 
Ca2+ extrusion or intracellular store Ca2+ buffering. As a compensatory 
mechanism for impaired extrusion, CSM may increase Ca2+ buffering into 
intracellular cellular stores to reduce cytosolic levels. Increases in the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression (53) and 
function (53;129) has been observed in CSM from pigs with  “early stage” CAD. 
Increased SERCA buffering could also explain the heightened caffeine-sensitive 
Ca2+ release via ryanodine receptors on the sarcoplasmic reticulum (SR) (Fig. 
4.4C). 
On the other hand, in “late stage” CAD, evidence has revealed a decrease 
in SERCA’s compensation (42), which could explain the decrease in our caffeine-
sensitive SR Ca2+ release observed in CSM from the pigs on atherogenic diet for 
12+  months (Fig. 4.4C). Studies have linked a decrease in SERCA activity to 
cCSM dedifferentiation to sCSM (130;131), however, we interpret our findings 
that increased SERCA in “early stage” CAD, as evident by increased caffeine-
sensitive Ca2+ store release (Fig. 4.4C), is characteristic of sCSM. Further along 
the CAD time course, as intimal sCSM reach a certain toxic Ca2+ threshold, the 
cell must adapt by inducing apoptosis or further dedifferentiating to the oCSM 
phenotype which is likely characterized by decreased SERCA (Fig. 4.4C).  
The early increase in SERCA may also occur in order to combat the 
increase in voltage-gated Ca2+ channel (VGCC) activity and expression that has 
been observed in CSM from pigs with a similar state of early CAD (56). Here we 
have provided more evidence, by both coronary ring tension development (Fig. 
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4.3C) and CSM Ca2+ influx (Fig. 4.4B), for increased VGCC activity from pigs 
with “early stage” CAD. Upregulated VGCC has also been observed in a cell line 
of cultured arterial smooth muscle cells exposed to low-density lipoprotein (132). 
Although their findings were in human cardiac myocytes, Schröder et al. found 
increased availability and open probability of VGCC from left ventricular samples 
from heart failure versus non-heart failure patients (133). This shift in VGCC 
properties is reflected in our Ca2+ signaling data of CSM from pigs with “early 
stage” CAD.  
 Downregulation of VGCC has been shown in dyslipidemic swine (53;55). 
Bowles et al. accounted their observed decrease in VGCC to the 
hypercholesterolemia of their pigs (55), however, our pigs with the highest level 
of total cholesterol (9 months on diet) revealed the highest coronary ring tension 
development along with the largest amount of VGCC Ca2+ influx (Table 1). If 
VGCC are downregulated in sCSM, inhibition should not prevent CSM 
dedifferentiation, which was shown by Kaimoto et al. in cell culture and in rats 
(134). It is feasible to conclude that VGCC is upregulated in early CAD when 
CSM begin to proliferate and migrate, and then severely downregulated in later 
CAD when complicated lesions containing apoptotic and oCSM exist. However, a 
major question lingers: does downregulation of VGCC lead to CSM 
dedifferentiation or does CSM dedifferentiation lead to downregulation of VGCC? 
 While it is important to recognize changes in Ca2+ handling associated 
with CSM phenotype switching, future studies must focus on causal roles for 
these changes. Transient receptor potential 1 channel (TRPC1) expression has 
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been correlated with neointimal growth and sCSM in humans (57). TRPC 
expression and activity are also increased in MetS Ossabaw (44). A causal role 
for TRPC1-mediated Ca2+ influx in CSM proliferation was proposed because 
TRPC1 activity preceded IVUS-detectable CAD in the disease time course (135). 
We used an organ culture model of vascular calcification (105) to 
investigate whether Ca2+ influx via VGCC plays a causal role in dedifferentiation 
to the oCSM phenotype. We confirmed oCSM dedifferentiation by identification of 
increased RUNX2 expression after CA organ culture using flow cytometry as 
previously described (136) (data not shown).  It is reasonably well accepted that 
dedifferentiated CSM have a decrease in VGCCs and contractile characteristics 
(137;138), but studies suggest a causal role of VGCC in calcification (139;140). 
Evidence for inhibition of vascular calcification by VGCC antagonists has been 
shown in in vitro (127) and animal (139) models and in humans (140) with 
vascular calcification. However, the mechanism of VGCC antagonist attenuation 
of disease is not well understood and it still remains uncertain whether Ca2+ influx 
by CSM directly affects calcification (30).  
Some functional differences were revealed by isometric tension studies; 
however, the lack of a phenotypic difference makes interpretation difficult. What 
we can determine from the functional data is viability of our tissue after 7 days in 
culture.  
Overall, these data support a conclusion that VGCC activity is not likely 
involved in the induction of coronary artery calcification by oCSM. The most 
convincing observation was the induction of calcification in rings that were 
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exposed to the VGCC inhibitor, nifedipine (Fig. 4.5D(a)). We are confident the 
inhibitor was effective because of the blunting of tension development observed 
in NIF cultured coronary rings (Fig. 4.6C). Interestingly, dispersed CSM from NIF 
cultured rings did not reveal decreased Ca2+ influx via VGCC upon K+ exposure 
(Fig. 4.7D). We speculate that nifedipine was not thoroughly washed from the 
intact rings prior to isometric tension studies.  
It seems reasonable that VGCC do not play a causal role in oCSM 
phenotype switching because expression is down in sCSM. In CAD, intimal 
plaque buildup due to proliferative sCSM occurs prior to extracellular calcification 
by oCSM. Because oCSM suffers from Ca2+ overload, it is likely that some other 
Ca2+ influx pathway is responsible. The TRPC family of sarcolemmal channels, 
specifically TRPC1, which has previously revealed a causal role in sCSM 
proliferation and its expression is increased in CSM from pigs with CAD 
(44;57;135), may likely play a role in oCSM dedifferentiation. 
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Figures & Tables 
 
Figure 4.1. Intracellular Ca2+ signaling in coronary smooth muscle cells. A. 
A model of CSM Ca2+ signaling. VGCC = voltage-gated Ca2+ channel; CP = Ca2+ 
pump; NX = Na+-Ca2+ exchanger; S = SERCA (sarcoplasmic-endoplasmic 
reticulum Ca2+) pump; TRP = Transient receptor potential channel; CAF = 
caffeine; CaC= cytosolic Ca2+; CaSR= intracellular store Ca2+; Green arrow= 
VGCC Ca2+ influx; Blue arrows: CAF-sensitive SR Ca2+ store release; Red X= 
Ca2+ buffering impairment during CAF exposure; Red arrow (dashed)= store-
operated Ca2+ influx; red arrows= impaired Ca2+ buffering/extrusion. B. 
Representative tracing of CSM cytosolic Ca2+ flux during imaging experiment. 
Labels indicate solution changes through superfusion chamber with duration 
shown by the horizontal lines. VGCC = voltage-gated Ca2+ channel; Caf = 
caffeine; green area under the curve = Ca2+ influx due to VGCC activation after 
80 mM K+ membrane depolarization; blue double-headed arrow = Ca2+ transient 
due to Caf-sensitive release of the intracellular SR Ca2+ store; red double-
headed arrow = delayed recovery to basal CC levels due to impaired Ca2+ 
buffering and store-operated influx.  
 
Figure 4.2. Intravascular ultrasound imaging of coronary arteries with 
varying stages of coronary artery disease. A. Cross-sectional view of a 
coronary artery from a lean pig reveals no evidence of intimal thickening of CAD. 
B. Cross-sectional view of a coronary artery from a MetS pig with “early stage” 
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CAD. A thin layer of concentric intimal thickening can be seen between the 
elastic lamina (yellow dotted line) and the lumen (red dashed line). C. Cross-
sectional view of a coronary artery from a MetS pig with “late stage” CAD. Plaque 
burden can be quantified between the lamina (yellow dotted line) and the lumen 
(red dashed line). Within this luminal narrowing lesion, bright white areas of 
calcification (traced in solid green lines) can be observed as evident by the 
acoustic shadowing effect in the adventitial region (green dotted lines). D. CAD 
progression was quantified by both wall coverage and plaque burden. CAD 
continues to progress in MetS pigs that are fed an atherogenic diet over a longer 
course of time with wall coverage significantly increasing in “early stage” CAD (0-
9 months) and plaque burden not increasing until “late stage” CAD (orange box, 
>9 months). (lean= 4 pigs, MetS 6 months= 5 pigs, MetS 9 months= 5 pigs, MetS 
12+ months= 7 pigs) Distance between blue dots is 1 mm.  
 
Figure 4.3. Functional assessment of coronary rings with varying stages of 
coronary artery disease. A. Age of lean pigs had no effect on tension 
development to 20 mM KCl. B. Coronary rings from MetS pigs fed an 
atherogenic diet for 9 months revealed the greatest tension development 
compared to rings from MetS pigs on diet for both 6 and 12+ months. C. 
Coronary rings from MetS pigs were paired with rings from age-matched leans. 
After 9 months on atherogenic diet, rings from MetS pigs acquired greater 
tension to 20 mM KCl compared to age-matched lean pigs (5.03 ± 0.94 g vs 1.36 
± 0.29 g, p<0.05. After 12+ months on atherogenic diet, rings from MetS pigs 
114 
 
acquired less tension to 20 mM KCl compared to age-matched lean pigs (0.70 ± 
0.08 g vs 2.82 ± 0.35 g, p<0.05). (lean= 9 pigs, MetS 6 months= 6 pigs, MetS 9 
months= 3 pigs, MetS 12+ months= 3 pigs)      
 
Figure 4.4. Intracellular Ca2+ imaging of freshly dispersed coronary smooth 
muscle cells. A. The same representative tracing from Figure 4.1B, is replicated 
here for aid in data interpretation. B. Coronary smooth muscle (CSM) from MetS 
Ossabaw fed an atherogenic diet for 9 months revealed increased Ca2+ influx via 
voltage-gated Ca2+ channels (VGCC) due to exposure to 80 mM KCl compared 
to 6 and 12+ months (dashed lines, one-way ANOVA and SNK, 17.6 ± 2.3 vs 7.7 
± 0.5  and 9.1 ± 1.0, p<0.05). This increase in VGCC Ca2+ influx was also greater 
compared to CSM from age-matched lean pigs (solid line, two-way ANOVA and 
SNK, 17.6 ± 2.3 vs 10.1 ± 0.7, p<0.05). C. CSM from MetS Ossabaw fed an 
atherogenic diet for 9 months revealed increased Ca2+ release via ryanodine 
receptors after exposure to 5 mM caffeine compared to 6 and 12+ months 
(dashed line, one-way ANOVA and SNK, 0.41 ± 0.07 vs 0.17 ± 0.02 and 0.16 ± 
0.02, p<0.05). This increase in caffeine-sensitive Ca2+ release was also 
increased compared to CSM from age-matched lean pigs (solid line, two-way 
ANOVA and SNK, 0.41 ± 0.07 vs 0.20 ± 0.01, p<0.05). D. By two-way ANOVA 
testing, no significant difference was revealed in sustained Ca2+ signal in CSM 
from MetS vs age-matched leans. However, MetS data alone showed an 
increase in the sustained Ca2+ signal in CSM from MetS Ossabaw fed an 
atherogenic diet for 9 months compared to 6 and 12+ months (dashed lines, one-
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way ANOVA and SNK, 0.08 ± 0.01 vs 0.05 ± 0.01, p<0.05, and 0.04 ± 0.01, 
p<0.05). (lean= 9 pigs, cells= 60; MetS 6 months= 6 pigs, cells= 56; MetS 9 
months= 7 pigs, cells= 68; MetS 12+ months= 9 pigs, cells= 92) 
 
Figure 4.5. An organ culture model of coronary artery calcification. A. Fresh 
coronary arteries were fixed and stained for mineral (calcification) and collagen 
deposition. As expected, fresh tissue showed healthy coronary smooth muscle 
(red) in the medial layer of the arterial wall with little collagen deposition (blue) by 
Masson’s trichrome staining (a) and no evidence of calcification (black/brown) by 
von Kossa mineral staining (b). B. After 7 days in control (CON) media, coronary 
rings lost the nice organization and structure of the medial wall seen in fresh 
rings, especially near the lumen suggesting medial inward thickening (a), and did 
not show any evidence of calcification (b). C. Rings cultured for 7 days in 
calcification (CA) media did not have increased medial thickening or collagen 
deposition (a&b), however, early calcification was induced in the media near the 
lumen (c&d). D. While not evident in all rings cultured in calcification + nifedipine 
(NIF) media for 7 days, calcification was induced in the same area as seen in CA 
rings (a). A closer look at the area of calcification reveals collagen deposition 
(blue) (b). A= adventitia; M= media; L= lumen; black arrows point to some but not 
all areas of calcification. (Fresh= 4 pigs, 4 rings; CON= 4 pigs, 8 rings; CA= 4 
pigs, 8 rings; NIF= 4 pigs, 8 rings) 
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Figure 4.6. Functional assessment of cultured coronary rings. A. Rings 
cultured for 4 and 7 days in the control (CON) media were functionally no 
different than fresh rings after exposure to 10, 20, or 80 mM KCl. Tension 
development to 20 mM KCl was significantly increased after 7 days in culture 
compared to just 4 days (5.0 ± 1.4 g vs. 1.4 ± 0.3 g, p<0.05). B. After 4 days in 
CA media, tension development was not different compared to fresh rings, but 
after 7 days a significant increase in tension development to 20 mM KCl 
compared to just 4 days was observed (5.3 ± 0.6 g vs. 2.3 ± 0.5 g, p<0.05). 
Rings cultured in CA media for 7 days had a significant increase in tension 
development from 20 mM KCl compared to fresh rings (5.3 ± 0.6 g vs. 2.8 ± 0.6 
g, p<0.05) and 80 mM KCl (8.1 ± 0.8 g vs. 6.3 ± 0.7 g, p<0.05) stimulation. C. 
Tension development of rings from 4 days in NIF media was severely blunted to 
both 20 mM KCl (0.4 ± 0.1 g vs. 2.8 ± 0.8 g, p<0.05) and 80 mM KCl (1.1 ± 0.3 g 
vs. 6.3 ± 0.7 g, p<0.05) compared to freshly isolated rings. After 7 days in culture, 
tension development to 80 mM KCl was still severely blunted compared to freshly 
isolated rings (1.7 ± 0.4 g vs. 6.3 ± 0.7 g, p<0.05) while tension development to 
20 mM KCl recovered to be functionally no different. There was no functional 
difference between 4 and 7 days of NIF media. (* indicates Day 0 vs Day 4, + 
indicates Day 0 vs Day 7, # indicates Day 4 vs Day 7; green=CON, blue=CA, 
red=NIF) D. Tension development to 20 mM KCl was blunted after 7 days in NIF 
media compared to rings cultured in both CA media (5.3 ± 0.6 g vs. 1.5 ± 0.3 g, 
p<0.05) and CON media (5.0 ± 1.34 g vs. 1.5 ± 0.3 g, p<0.05). There was no 
significant difference between overall tension developments of rings in CON 
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media compared to CA media. E. Tension development to 80 mM KCl was 
blunted after 4 days in NIF media compared to rings cultured in both CA media 
(8.3 ± 0.9 g vs. 1.1 ± 0.3 g, p<0.05) and CON media (5.7 ± 1.0 g vs. 1.1 ± 0.3 g, 
p<0.05). Tension development to 80 mM KCl was still blunted after 7 days in NIF 
media compared to rings cultured in CA media (8.1 ± 0.8 g vs. 1.7 ± 0.4 g, 
p<0.05) and CON media (6.6 ± 1.6 g vs. 1.7 ± 0.4 g, p<0.05). There was no 
significant difference between overall tension developments to 80 mM KCl of 
rings in CON media compared to CA media. (* indicates CON vs CA, + indicates 
CON vs NIF, # indicates CA vs NIF; green=CON, blue=CA, red=NIF) (Day 0-
Fresh= 4 pigs, 16 rings; Day 4-CON= 4 pigs, 9 rings; Day 4-CA= 4 pigs, 10 rings; 
Day 4-NIF= 4 pigs, 9 rings; Day 7-CON= 4 pigs, 10 rings; Day 7-CA= 4 pigs, 10 
rings; Day 7-NIF= 4 pigs, 8 rings) 
 
Figure 4.7. Intracellular Ca2+ imaging of coronary smooth muscle cells from 
cultured rings. A. A representative tracing of the experimental protocol 
performed on cells dispersed from cultured coronary rings. B. No difference in 
baseline Ca2+ was observed in fresh and all CSM from cultured rings. C. 
Sarcoplasmic reticulum caffeine-sensitive Ca2+ release was significantly greater 
in fresh CSM compared to CSM from cultured rings. No difference was observed 
between all culture groups, but a trend of further decreased Ca2+ release was 
seen in CSM from CA rings. D. The rate of Ba2+ influx was not different between 
fresh or any CSM from cultured rings. (Day 0-Fresh= 4 pigs, 57 cells; Day 4-
CON= 4 pigs, 49 cells; Day 4-CA= 4 pigs, 43 cells; Day 4-NIF= 4 pigs, 48 cells; 
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Day 7-CON= 4 pigs, 42 cells; Day 7-CA= 22 cells, 10 rings; Day 7-NIF= 4 pigs, 
23 cells) 
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Figure 4.1.  
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Figure 4.2.  
 
  
121 
 
Figure 4.3.  
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Figure 4.4. 
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Figure 4.5. 
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Figure 4.6.  
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Figure 4.7.  
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Table 4.1. Metabolic characteristics of Ossabaw miniature swine groups.  
 
Lean MetS 6 months 
MetS 
9 months 
MetS 
12 months Significance 
Body weight 
(kg) 62 ± 5 89 ± 2 87 ± 7 116 ± 2 
12 > 9, 6 > 
lean 
Fasting Blood 
Glucose (mg/dL) 84 ± 6 75 ± 2 82 ± 7 81 ± 2 NS 
Systolic Blood 
Pressure (mmHg) 131 ± 7 150 ± 9 143 ± 4 170 ± 7 12, 9, 6 > lean 
Diastolic Blood 
Pressure (mmHg) 63 ± 2 77 ± 5 85 ± 4 89 ± 5 12, 9 > 6, lean 
Total Cholesterol 
(mg/dL) 57 ± 5  383 ± 39 546 ± 66 247 ± 17 
12 > 9 > 6 > 
lean 
Triglycerides 
(mg/dL) 25 ± 4 34 ± 4 98 ± 34 43 ± 6 9 > 12, 6, lean 
All measures were tested by One-way ANOVA and SNK post-hoc.  
NS = not significant. 
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CHAPTER 5: CONCLUSION 
Summary of Findings 
“Syndrome X” (5), “the deadly quartet” (141), and “a secret killer” (142) —all 
pseudonyms that have been used to describe metabolic syndrome (MetS), the 
condition with which 1/3 of Americans are diagnosed (143;144). It is well 
recognized that MetS is a risk factor for cardiovascular disease (CAD) and 
cardiovascular mortality. In 2006, Galassi et al. released their findings from an 
extensive literature search for studies that examined the association between 
MetS and CAD spanning almost 40 years (1966-2005) (145). From this analysis 
it was concluded that patients with MetS have a 61% increased risk for CAD 
(145), which is well-known as the leading killer of Americans (8). 
To coincide with the high incidence in the United States, we have conducted our 
investigative aims using the Ossabaw swine model of MetS and CAD (39-44) to 
better replicate the human patient. Following is the summary of findings from this 
thesis research: 
 
Investigative Aim 1. Coronary epicardial adipose tissue (cEAT) contributes 
directly to CAD in Ossabaw swine and CAD progression was attenuated upon 
surgical removal of the local fat depot. 
The results of our pilot study are consistent with the hypothesis that 
selective coronary artery adipectomy attenuates the progression of early 
atherosclerosis. Along with attenuation of disease progression, multiple 
inflammatory markers were reduced at the site of adipectomy compared to 
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neighboring intact sites and cEAT from MetS pigs expressed an increased 
amount of inflammatory genes compared to control cEAT. These findings support 
the notion that local cEAT contributes to CAD by contributing to the inflammatory 
response within the coronary artery wall. 
 
Investigative Aim 2. 18F-NaF uptake in the coronaries of MetS Ossabaw with 
early stage atherosclerosis was higher than in lean Ossabaw and 18F-NaF uptake 
can be detected at a stage prior to that measurable by computed tomography 
(CT). 
In this preclinical positron emission tomography (PET) study, we have 
demonstrated that increased 18F-NaF uptake in the coronaries can detect early 
calcium metabolism in pigs with clinically insignificant CAD that lack evidence of 
calcification by both intravascular ultrasound (IVUS) and CT imaging. These 
findings render the interpretation that 18F-NaF binds to microcalcifications that 
are on a molecular level, which is too small to be detected using other imaging 
modalities. 
 
Investigative Aim 3. Coronary smooth muscle (CSM) Ca2+ signaling and 
function are increased in “early” CAD, but significantly decreased in “later” stages 
of CAD progression. More specifically, fluctuation of voltage-gated calcium 
channel (VGCC) activity had no role in osteogenic coronary smooth muscle 
(oCSM) dedifferentiation and CAD progression to coronary artery calcification 
(CAC). 
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In this time course study, we have demonstrated that CSM Ca2+ regulation is 
complex and changes as CAD progresses. In “early stage” CAD, coronary rings 
have increased vasoconstriction and their CSM have heightened Ca2+ signals. 
This is interpreted as an adaptation phase to the onset of a MetS milieu. If CAD 
progresses without intervention, coronary ring vasoactivity is dramatic blunted 
and CSM Ca2+ signaling is decreased as well. These findings suggest the 
importance of identifying the stage of disease at which measures are obtained. 
Further, we have demonstrated that VGCC inhibition does not inhibit CAC in 
organ culture, suggesting an alternative Ca2+ influx pathway is responsible. 
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Future Directions 
A large volume of evidence supports the hypothesis that epicardial 
adipose tissue (EAT) volume is associated with CAD (22;146-151) and 
cardiovascular events (64;152) in humans, however, this association is difficult to 
experimentally test due to its anatomical location and research ethics. Our study 
in the Ossabaw swine model of MetS and CAD was the first of its kind in 
experimentally investigating the influence of cEAT on CAD progression (21). To 
more definitively connect the physical presence of cEAT and its impact on CAD, 
our initial study should be repeated with more pigs and using a definitive marker 
for the exact adipectomy location. With increasing the number of pigs, a sham 
group can serve as controls rather than the intra-animal controls used previously 
(21). Using an intra-animal control resulted in comparison of CAD progression 
between the LAD and CFX artery of each pig. While this was cost-effective, 
disease varies amongst the coronaries (153;154) and, therefore, a better control 
would be a sham LAD of another pig. Also, while CAD is diffuse in MetS 
Ossabaw (155), the greatest amount of disease remains in the proximal region of 
the LAD (153-155). Therefore, the adipectomy should be performed in the 
proximal region to observe greater and more obvious changes in CAD 
progression between groups. Finally, during the adipectomy procedure, it would 
be ideal to place radiopaque and echogenic markers at the proximal and distal 
locations (Fig. 5.1A) to ensure exact localization of the procedure site upon 
euthanasia. Using both angiography (Fig. 5.1B) and IVUS (Fig. 5.1C) to detect 
the markers, the location and length of the adipectomy region can be determined.  
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Studies have also found that intrapericardial adipose tissue, lying directly 
on top of the coronary arteries and myocardium, is associated with CAD risk 
factors and more specifically, CAC (22;156;157). CAC is in part a result of local 
inflammation due to macrophage secretion of cytokines that promote CSM 
osteogenic dedifferentiation (86;158;159). Our 18F-NaF PET/CT study in 
Ossabaw swine was the first study to our knowledge to attempt to image CAC at 
such an early stage of CAD. At this stage, the CAD was clinically insignificant, 
with little plaque burden and no evidence of calcium by CT. Future studies of 18F-
NaF should entail much more variation in disease to better understand the 
characteristics of 18F-NaF uptake throughout the time course of CAD/CAC. A 
hypothetical time course can be seen in Figure 5.2. 
Prior to the formation of microcalcifications is a stage of local 
inflammation, which has interested researchers as a target for an in vivo imaging 
diagnostic tool. 18F-fluorodeoxyglucose (FDG), a PET tracer that indicates 
glucose metabolism, has been investigated as a potential marker for 
macrophage activity in atherosclerotic plaque (108;109;111) (Fig. 5.2A). The 
downfall of 18F-FDG has been its low target to background ratio in the heart due 
to glucose metabolism of the myocardium, evidenced by experimental findings 
(38). Aikawa et al. showed with in vivo imaging the close proximity of 
inflammation and calcification (86). While inflammation contributes to 
microcalcification, microcalcification activates macrophages in a positive-
feedback fashion (84;85). This cycle will continue to drive more calcification if no 
clinical intervention takes place. We also know these microcalcifications increase 
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the risk of plaque rupture (91-93). It would seem that this is a critical stage in 
CAD/CAC progression where clinicians would want to identify patients using 18F-
NaF (Fig. 5.2B). Early diagnosis could assist in augmentation of disease 
progression perhaps by anti-inflammatory treatment at a reversible stage of 
CAD/CAC. It has also been suggested that reducing inflammation at this stage 
will aid in plaque stability (87). Further progression of CSM osteogenic 
dedifferentiation will result in macrocalcifications characterized by reduced 
inflammation and large, but stable calcified atherosclerotic lesions. Unfortunately, 
it is thought that macrocalcifications at this stage are irreversible. This is the 
stage at which CT can detect calcium in the heart (Fig. 5.2C). Interestingly, 
Dweck et al. found that 41% of patients with Agatston scores >1000 revealed no 
18F-NaF uptake (160). Therefore, it will be important to investigate the threshold 
at which active microcalcification ends and stable, quiescent macrocalcification 
begins. Future studies in animal models should focus on the time course of 18F-
NaF uptake across the disease spectrum. Ideally, animals with varying stages of 
disease can be imaged along with other ex vivo measures such as 
histopathology and protein/gene expression in order to better characterize 
CAD/CAC and CSM involvement.  
The changes in CSM Ca2+ handling during transition from contractile CSM 
(cCSM) to synthetic CSM (sCSM) seems to be well characterized (161;162); 
however, little is understood about oCSM.   With efforts in better understanding 
the time course of Ca2+ handling changes, we performed fura-2 Ca2+ imaging 
studies of CSM from pigs with progressing stages of CAD. To expand on the 
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associations we found and that were described in chapter 4, we specifically 
targeted the VGCC as a putative source of Ca2+ influx leading to oCSM 
dedifferentiation and activity because we saw increased activity in CSM from our 
pigs with “early stage” CAD. From our findings we concluded that VGCC activity 
did not play a causal role in CAC. 
Future studies of CSM Ca2+ signaling should be more focused on specific 
Ca2+ transporters and their causal roles in CAD progression. For example, a 
causal role for TRCP1 has been found in dedifferentiation and proliferation in 
human saphenous vein (57) and pig (163) CSM.  Additionally, Neeb et al. found 
that TRPC1 Ca2+ influx preceded CAD in MetS Ossabaw, further supporting its 
causal role in proliferation (135). Future studies should investigate the role of 
TRPC1 in oCSM dedifferentiation. It seems probable that a Ca2+ influx pathway 
will be responsible considering the cells are overloaded with Ca2+ (164) prior to 
the protective onset of matrix vesicle loading (165) (Fig. 5.3). Because we know 
sCSM express TRPC1, it is logical to think oCSM may as well. Rather than a 
linear path of dedifferentiation (cCSM → sCSM → oCSM), it is more likely an 
adaptation of cCSM to sCSM and/or oCSM to avoid apoptosis.  
In the setting of chronic kidney disease, patients have medial calcification 
rather than atherosclerotic intimal calcification. In this case, cCSM in the medial 
layer of the arterial wall may be dedifferentiating directly to oCSM due to Ca2+ 
overload. Previously, we were not capable of imaging molecular calcification, but 
with 18F-NaF we provided evidence that molecular calcification is occurring much 
earlier in the disease time course than we had thought. Concurrently, we may 
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find that TRPC1 channels are contributing to dedifferentiation and the Ca2+ 
overload of the oCSM phenotype. Increased Ca2+ influx past a certain threshold 
triggers matrix vesicle formation (113;164) and it is well understood that these 
matrix vesicles are loaded with calcification ingredients and dumped from oCSM 
into the extracellular matrix where hydroxyapatite calcifications are found (166). 
Another future direction for investigating CSM Ca2+ handling would be to try and 
better understand the effect of oCSM Ca2+ overload on matrix vesicle formation 
and dumping (Fig. 5.3.). Interestingly, microvesicles (smaller than matrix 
vesicles) have been found in athero-prone areas of human aorta (116). More 
specifically, these microvesicles are from intimal CSM at the pre-disease stage. 
This could be occurring in the early stage of transition from cCSM to sCSM prior 
to any intimal thickening. Also it is important to note that these microvesicles do 
not contain calcifying reagents; in fact, they contain inhibitors of calcification 
(116). It could be possible that CSM Ca2+ dysfunction as CAD progresses is what 
leads to the transition from protected microvesicles to pro-calcifying matrix 
vesicles.  
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Closing Remarks 
 This accumulation of research has led to the following all-encompassing 
working model: In the setting of MetS and CAD, cEAT is increased and therefore 
local inflammation around the conduit coronary artery. Pro-inflammatory factors 
and the MetS milieu disturb the quiescent CSM initiating intracellular Ca2+ 
dysregulation and dedifferentiation (Fig. 5.2A). Ca2+ dysregulation leads to CSM 
Ca2+ overload and progression of CAD. Further Ca2+ dysfunction in oCSM 
initiates adaptive matrix vesicle loading and extracellular microcalcification. At 
this stage, high inflammation and newly released microcalcifications are involved 
in positive feedback activity which can be detected by 18F-NaF, but not the 
clinically standard CT (Fig. 5.2B). Diagnosis at this stage would be beneficial in 
disease intervention as risk of plaque rupture is increased due to 
microcalcification deposition in thin fibrous caps. If left untreated and no 
detrimental cardiovascular event occurs, microcalcifications will turn into large, 
stable macrocalcifications characterized by decreased inflammation and 
potentially blood flow limitations (Fig. 5.2C).  
It is critical that we further investigate the effects of adipose-derived 
inflammation on CSM Ca2+ regulation and dedifferentiation, the specific changes 
in CSM Ca2+ dysregulation as CAD/CAC progresses, and finally the time course 
of CAD/CAC progression on a molecular level to use more sensitive imaging 
tools for earlier diagnosis and therefore earlier patient treatment.    
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Figures 
 
Figure 5.1. Placement of ligature clips at the adipectomy site of MetS 
Ossabaw. (A) A retracted pericardial sac reveals two ligature clips at the 
adipectomy site above the LAD of a MetS pig. The adipectomy site is flanked at 
both proximal (yellow arrow) and distal (green arrows) ends. (B) An intravascular 
ultrasound (IVUS) image shows the echogenic ligature clip (green arrow) at the 
4-5 o’clock orientation of the vessel (red dashed line). The placement of the clips 
can be imaged at the time of the adipectomy surgery; however, in the case that 
the clips fall off of the heart, anatomical landmarks can be used to identify the 
adipectomy site at euthanasia (~3 months post-surgery). In this image, a branch 
point can be seen at the 11 o’clock orientation of the vessel. Distance between 
dots is 1 mm. (C) The radiopaque clips can also be visualized by angiography 
(yellow and green arrows). (D) By flushing the coronary tree with contrast, 
anatomical landmarks can also be visualized by angiography. Traced in white, 
the same small branch seen in the IVUS image in panel B can be identified with 
angiography. This particular branch is faint, but more easily identified on the 
looped angiography video. The same distal clip is identified by the green arrow.  
 
Figure 5.2. Multiple clinical imaging modalities can be used to assess 
progression of coronary artery disease and calcification. (A) Prior to the 
onset of coronary artery calcification (CAC) is a stage of coronary artery disease 
(CAD) characterized by macrophage infiltration and lipid deposition of the arterial 
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wall, and increased local inflammation detectable by 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET). (B) As inflammation remains, 
arterial intimal thickness and complexity increase due to dedifferentiation of 
coronary smooth muscle (CSM) to the osteogenic phenotype. CSM osteogenic 
activity leads to extracellular deposition of microcalcifications detectable by 18F-
NaF PET. Evidence suggests that this combination of chronic inflammation and 
active calcification in “early stage” CAD increases the risk of plaque rupture. 
Because these lesions are not flow-limiting, they are frequently asymptomatic, 
which is dangerous considering their risk of rupture. It is critical to identify 
patients at this stage of CAD/CAC. (C) Without intervention, and if a patient 
survives a plaque rupture event, the plaque will heal and CAD/CAC will progress 
to “later stage” CAD characterized by hardened, collagen-rich plaque containing 
large macrocalcifications. These large lesions can be stenotic (flow-limiting), but 
are likely stable due to reduced inflammation and stable calcium turnover (similar 
to mature bone activity). At this stage, macrocalcifications can be detected by 
computed tomography (CT) and IVUS.  
 
Figure 5.3. Coronary smooth muscle cell adaptation to increased Ca2+ 
influx and local adipokines signaling.  Coronary smooth muscle cells (CSM) 
are well known for their adaptive plasticity to the local environment. In the setting 
of obesity and metabolic syndrome (MetS), increased coronary epicardial 
adipose tissue (cEAT) volume is associated with increased CAD/CAC. 
Adipokines release from the local cEAT have been shown to effect CSM ion 
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channel function (75). These adipokines may penetrate the arterial wall or reach 
the CSM via the vaso vasorum where their effects influence CSM Ca2+ signaling 
and dedifferentiation to synthetic (sCSM) and osteogenic (oCSM) phenotypes. 
Specifically, sCSM are known to express increased TRPC1, potentially to 
compensate for the decrease in voltage-gated channel activity in “later stage” 
CAD. Increased sCSM/oCSM secretory activity increases the complexity of the 
extracellular matrix by collagen (purple rods), elastin (black ripple lines), and 
matrix vesicle deposition (light blue circles). Hypothetically, in “early stage” CAD, 
when CSM sarcoplasmic reticulum (SR) Ca2+ is elevated, sCSM vesicular activity 
is increased resulting in synthesis of extracellular matrix proteins 
(collagen/elastin). This forms an ideal environment for extracellular calcification 
(dark blue crystals, hydroxyapatite). Prior to the osteogenic phenotype, vesicles 
released from CSM to protect from intracellular Ca2+ overload will contain 
calcification inhibitors. Concurrently, and/or in “later stage” CAD, oCSM 
(characterized by RUNX2 and Ca2+ overload) adapt to adveristy by matrix vesicle 
release. Matrix vesicles are released into the extracellular matrix where they lay 
down hydroxyapatite on elastic/collagen fibers, contributing to plaque instability. 
Osteogenic matrix vesicles can transport Ca2+ and PO43-, and due to lost 
calcification inhibitors can pre-form hydroxyapatite before release.  
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Figure 5.1. 
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Figure 5.2. 
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Figure 5.3.  
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APPENDIX A 
PROCOTOL FOR 18F-NAF PET/CT IMAGING OF OSSABAW SWINE 
Paul R. Territo, Ph.D.,10/02/12; Mikaela L. McKenney, 07/31/14  
Study Protocol Title: Does high calcium intake exacerbate Atherosclerosis 
Standard Conditions: 
The Standard Conditions section includes baseline parameters for this model; 
Briefly describe differences below and in detail as necessary in the body of the protocol. 
Number of Animals 24 
Number of Treatment Groups 2 
Dosing Routes IV – PET 
IV – CT 
Dosing Frequency IV – 1/PET 
IV – 1/CT 
Strains Ossabaw  
Sex Female 
Species (1 per Template) Swine 
Duration of Live Phase 8 weeks 
Study Type chronic 
Endpoints PET/CT 
Deliverables Raw Images, Summary Data 
Is this a Standard Study? NO   
If NO, briefly describe Non-
Standard Conditions  
This project will combine gated PET for 
determination of cardiac vascular 
calcifications with traditional measures 
acquired with gated CT angiography. 
 
IIBIS Resource Areas: 
Resource Needs: Clinical Pathology 
Histology 
Necropsy 
Animal/Vet Care 
Dose Formulations 
Sample Processing  
Surgery  
Imaging 
Imaging Histology  
Flow Cytometry 
Other:  
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1. Study Summary:  
IIBIS Study Number 2013-00055 
Sponsor Reference Number 
(Optional) 
Ossabaw 26 
Regulatory Status: Non-GLP 
Sponsor IACUC Protocol 3645 
IIBIS IACUC Protocol N/A 
Test Facility: IIBIS Core 
Department of Radiology & Imaging Sciences 
Indiana University 
950 West Walnut, R2 
Indianapolis, IN 46202 
IIBIS PI Paul R. Territo, Ph.D 
Assay Name: Large animal imaging 
Assay Type: Acute 
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Research Area: Cardiovascular 
What are the deliverables: Raw Images 
Raw Data 
Annotation Table 
Analysis Data  
Parametric Images 
Graphs/Figures 
Statistical Analysis 
Specimens 
(Tissue /Samples) 
Animals (Surgery) 
Other:       
 
Interim Report 
Final Report 
Study Purpose: The purpose of the current study is to 
determine vascular calcification via NaF PET, 
and CTA methods. 
Success Measures: Successful completion of the live phase.  
Expected Quantitative 
Controls: 
Historical Study Data: No 
Study References:  N/A 
Positive Control Value:  N/A 
Negative/Vehicle Control Value:  
Variability within replicates: <50% 
Minimum # of surviving animals/grp at end of 
study: 23 
Assay Specific Criteria: N/A 
Assay Type: Exploratory (Pilot) 
Model Development 
Pharmacological Validation 
Statistical Validation 
Model Transfer 
Other:       
 
2. Key Personal: 
2.1. Sponsor’s  Personnel 
Sponsor Scientist: Michael Sturek, Ph.D 
Phone: (317) 274-7772 
Email: msturek@iupui.edu 
  
Sponsor Scientist: Mouhamad Alloosh, MD 
Phone: (317) 503-4671 (cell) 
Email: malloosh@iupui.edu 
  
Sponsor Scientist: James Byrd 
Phone: (317) 278-3711 
(317)-362-3005 (cell) 
Email: jvucheti@iupui.edu 
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2.2. IIBIS Personnel 
IIBIS Scientist: Paul R Territo, Ph.D 
Phone: (317) 278-3313 
Email: pterrito@iupui.edu  
  
IIBIS Scientist: Gary Hutchins, Ph.D 
Phone: (317) 274-3687 
Email: gdhutchi@iupui.edu  
  
IIBIS Scientist: Yun Liang, Ph.D 
Phone: (317) 274-1843 
Email: yliang1@iupui.edu  
  
IIBIS Scientist: Mandy Riley, RLAT 
Phone: (317) 278-7414 
Email: amariley@iupui.edu  
  
IIBIS Scientist: Wendy Territo, CNMT, RT(R)(N) 
Phone: (317) 274-2570 
Email: wterrito@iupui.edu  
  
IIBIS Scientist: Kevin Perry, CNMT 
Phone: (317) 274-2570 
Email: kperry2@iupui.edu  
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3. Dosing and Formulations - PET 
Dose Description All dose materials will be pre-formulated 
as aqueous solutions of 18F-NaF 
Dosing: 1/subject @ 30-35mCi 18F-NaF 
Vehicle: Sterile Saline 
Correct for Specific Activity: N/A 
Frequency of preparation:   Per day (3 doses total) 
Dose Target Times: (1 dose/day) 
14:00-14:30 
 
(2 dose/day) 
14:00-14:30 
16:00-16:30 
Supplier: Siemens PETNet, to be ordered by IIBIS 
personnel at least 1 week prior to study 
conduct. 
Dose Uptake Interval 2.5h prior to initial PET scan 
Dose Route IV – Vascular access port via jugular vein 
Alt. Dose Route IV – Vascular access port via ear vein 
Dose Times: To be recorded according to atomic clock.  
Clock Calibration: 
(IIBIS Personnel) 
The atomic clock should be calibrated to 
the scanner time each day prior to study 
start. 
Disposition/disposal of Materials 
Provided: 
Per departmental SOP. All other 
materials and waste will be disposed of 
and documented by the sponsor. 
4. Dosing and Formulations - CT 
Dose Description All dose materials will be pre-formulated 
as aqueous solutions of Isovue 
Dosing: Isovue 370 – 125ml (76%) 
Power Injector Parts Medrad Stellant (P/N 130745) 
200ml syringe, 1 low pressure coil, 1 
spike. 
Dose Volume: 100 ml in total volume /subject  
Dose Rate: 4 ml/sec for 25 sec total 
Vehicle: Sterile Saline 
Supplier: To be ordered by IIBIS personnel at least 
1 week prior to study conduct. 
Dose Uptake Interval N/A 
Dose Route IV – Vascular access port via jugular vein 
Alt. Dose Route IV – Vascular access port via ear vein 
Dose Times: To be recorded according to scanner 
clock.  
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Disposition/disposal of Materials 
Provided: 
Per departmental SOP. All other 
materials and waste will be disposed of 
and documented by the sponsor. 
5. Animal Information 
Species: Swine 
Strain: Ossabaw 
Vendor: Purdue University - Breeding Program 
Sex: Female 
Age/Weight: 50-120kg 
Quantity to order N/A (supplied by sponsor) 
Quantity to enroll in the study: 24 
Acclimation during Pre-Treatment 
Phase: 
Per IACUC guidelines 
5.1. Diet and Water  
Diet Description/Supplier: Provided by sponsor: KT324 with three 
different calcium’s concentration 
Water Type: Indianpolis City Water  
5.2. Housing 
Housing: Individually house in USDA approved space at 
LARC 
Environmental Conditions: Photoperiod:  12 hours light, 12 hours dark 
(may be interrupted for study-related activities).  
The animals were placed in normal light cycle 
i.e. from 6 pm to 6 am (dark cycle).  
Temperature:  72 ± 8°F 
Relative humidity:  20% - 80%   
6. Pre-Treatment Phase 
Clinical Signs: Conducted by Sponsor  Personnel 
Body Weights: Prior Imaging – Provided by Sponsor 
Animal Distribution: Animals will be segregated into individual pens 
with unique identification.  
Pre-Treatment 
Requirements: 
Animals should be in good health and 
acclimated for at least 2 days prior to study 
conduct.   
7. Treatment Phase 
Feeding/Fasting 
(type/date/time): 
Animals should be fasted for a minimum of 12 
hours prior anesthetic induction and/or tracer 
administration. In all cases, animals will have ad 
libitum access to water. 
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8. Terminal Phase 
Animal Disposition: • Dosed animals that are found dead contact 
the sponsor and alternate sponsors at the 
above listed numbers and email with 
findings. 
• Animals are to be transferred to sponsor for 
disposition of carcass according to RSO and 
NRC guidelines. 
Euthanasia: Per IACUC protocol guidelines 
9. Necropsy Specimen Collection 
Collection methods: N/A 
10. Phamacokinetics (PK) 
Time Points: N/A 
 
11. Sample Analysis 
Sample Preparation: N/A 
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12. Study Procedures 
Study Overview 
In general, the study will composed of 18F-NaF list mode data acquisition with 
capture of ECG gating information.  Gated Cardiac PET sequence, 
retrospectively gated into 8-16 phases of the cardiac cycle depending on image 
SNR. In addition, Static Abdominal PET images will be acquired at 3 bed 
positions which will encompass abdominal aorta from the apex or the heart 
through to femoral bifurcation. At completion of the PET, prospectively gated 
unenhanced CT for coronary calcium scoring and Contrast Enhanced Gated 
Cardiac CT Angiography will be acquired and retrospectively gated into 8-16 
phases of the cardiac cycle, with matching bin alignment to PET sequence.  
Animal Preparation 
Up to 2 animals per day will be injected with 30-35mCi radiotracer described in 
“Dosing and Formulations - PET”, and after 2.5 hr of tracer uptake, each 
animal will be induced at the LARC facility with Telazol (4.5-6.6 mg/kg) with 
Xylazine (2.2 mg/kg), intubated, and maintained on 1-5% Isoflurane (balance 
medical air) during transport from LARC to the placement on the imaging bed at 
IUH (Rm. 1117). Upon completion of the PET sequence, each animal will be 
infused with 100ml total of Isovue 370 contrast using the Stellant power injector 
wit materials and methods described in “Dosing and Formulations - CT”. 
 
Study Sequence 
Animals will be imaged using Siemens Biograph 64 PET/CT located at IUH 
according to the protocols and parameters outlined in “Image Acquisition”. 
Images will be reconstructed according to the modality using the params found in 
the “Image Reconstruction” section of the protocol. In all cases, animals will 
generally follow the temporal sequence for study conduct as outlined in 
“Estimated Daily Study Schedules”, where group replicates will be performed 
at regular intervals detailed in the “Estimated Weekly Study Schedules”. 
 
Image Naming Convention 
Each animal’s images should be named such that they can be uniquely identified 
by combination of Animal ID and IIBIS ID, as illustrated below: 
 
Animal ID: Ossabaw Pig 2214 
IIBIS ID: 2013-00055 
 
PET/CT Field Name Example Values 
Last Name: Ossabaw_Pig_2214 
Patient ID: 2013_00055_ Ossabaw_Pig_2214 
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System: Siemens BioGraph 64 PET/CT 
Attenuation Sequence (1): CT TOPOGRAM 
Parameters (1):  
 
Collimation       64x0.625 mm 
Slice thickness    0.60 mm 
Slice increment   1.00 mm 
Slice length         1024mm 
Voltage       140 kV 
Current       35 mA 
mAs                  170 mAs 
Image matrix       512 x 512 
Orientation          Caraniocaudal 
Acquisition Sequence (2):  
(Gated Cardiac PET) 
PET_CARD_LM_SWINE 
Parameters (2):  
 
Isotope                18F 
Target Dose        10-15mCi 
Scan Mode          Listmode 
Scan Range        Match CT Localizer 
Scan Duration     30min 
Orientation          Caraniocaudal 
Trigger                ECG 
Attenuation Sequence (3): CT TOPOGRAM 
Parameters (3):  Collimation       64x0.625 mm 
Slice thickness    5.00 mm 
Slice length         1370mm 
Voltage       120 kV 
Current       35 mA 
mAs                  325 mAs 
Delay                  4 s 
Scan Time          24.57 s 
Image matrix       512 x 512 
Orientation          Caraniocaudal 
Acquisition Sequence (4):  
(Static Abdominal PET) 
1_PETCT_WHOLEBODY_SWINE 
Parameters (4):  
 
Isotope                18F 
Target Dose        10-15mCi 
Scan Mode          Normal 
Scan Range        Match CT Localizer 
Bed Count           3 
Scan Duration     5min/Bed 
Orientation          Caraniocaudal 
Trigger                None 
 
 
 
152 
 
Image Acquisition – CT/CTA 
System: Siemens BioGraph 64 PET/CT 
Acquisition Sequence (5):  
(Coronary Calcium Scoring) 
Coronary Calcium Scoring 
Parameters (5):  
 
Collimation       24x1.2 mm 
Slice thickness    1.20 mm 
Slice increment   1.20 mm 
Pitch                  1 
Rotation time       0.5 s 
FOV                  500 mm 
Voltage       120 kV 
Current       600 mA 
mAs                  300 mAs 
Image matrix       512 x 512 
CTDIvol       26.2 mGy 
Gating phase      65% 
Acquisition Sequence (6):  
(Gates-Contrast CTA) 
CORONARYCTA_STUREKPIG 
Parameters (6):  
 
Collimation       64x0.6mm 
Slice thickness    0.6 mm 
Slice increment   0.4 mm 
Pitch                  0.20 
Rotation time       0.33 s 
FOV                 180 mm 
Voltage      120 kV 
Current      606mA 
mAs                 1000 mAs 
Image matrix      512 x 512 
CTDIvol      47.0 mGy 
Contrast             Isovue 370 
Volume              100 Cc in total volume 
Injection Rate     4 cc/sec injection rate 
Gating phases    65%; and additional 16 in  
                           accordance with PET. 
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Image Reconstruction – PET 
 Acquisition Sequence (1):  CT TOPOGRAM 
Parameters (1):  
 
Method:              FBP 
SP Filter       Yes 
Adaptive Filter     N0 
Filter                  B 
Tagging       None 
Acquisition Sequence (2):  
(Gated Cardiac PET) 
PET_CARD_LM_SWINE 
Parameters (2):  
 
Model                 Offline 
Method               Backprojection 
Filter                   70% Hanning 
FWHM                2mm 
Zoom                  1.0 
Tagging       ECG 
Phases               16 
Attenuation Sequence (3): CT TOPOGRAM 
Parameters (3):  Method:              FBP 
SP Filter       Yes 
Adaptive Filter     N0 
Filter                  B 
Tagging       None 
Acquisition Sequence (4):  
(Static Abdominal PET) 
1_PETCT_WHOLEBODY_SWINE 
Parameters (4):  
 
Model                 Online 
Recon                 Backprojection 
Filter                   70% Hanning 
FWHM                2mm 
Zoom                  1.0 
Tagging       None 
 
154 
 
Image Reconstruction – CT/CTA 
Acquisition Sequence (5):  CORONARY CALCIUM SCORING 
Parameters (5):  
 
Method:              FBP 
SP Filter       Yes 
Adaptive Filter     No 
Filter                  B35F Heart View Medium 
Tagging       65% 
Acquisition Sequence (6):  
(Gated-Contrast CT) 
CORONARYCTA_STUREKPIG 
Parameters (6):  
 
Method:              FBP 
SP Filter      Yes 
Adaptive Filter    Yes (Cardiac) 
Filter                 B25F smooth ++ 
Tagging      ECG: 65% A 
Phases              16 
 
Image Quantification 
1. PET Imaging 
PET images will be co-registered to CT images using a mutual information 
based normalized entropy, 3D-Voxel Registration, algorithm in Analyze 11.0 
(AnalyzeDirect, BIR Mayo Clinic).  CT images will be segmented into blood 
pool (cardiac chambers and major vessels) and myocardial tissue using 
either: 1) Object Extractor, an object based region growing algorithm, or 2) 
Manual segmentation. Segmented blood pool and myocardial tissue VOIs will 
then be applied to PET images and SUV (or %ID/g) in each volume of interest 
(VOI) will be calculated according to standard methods described previously 
[1]. In all cases, image segmentation and image quantification will be 
performed using Analyze 11.0 software (AnalyzeDirect, BIR Mayo Clinic).  
2. CT/CTA Imaging 
PET images, where appropriate, will be co-registered to CT using a mutual 
information based normalized entropy, 3D-Voxel Registration, algorithm in 
Analyze 11.0 (AnalyzeDirect, BIR Mayo Clinic) software according to [2]. 
Gated Non-Contrast CT  will be analyzed utilizing the Philips EBW(Extended 
Brilliance Workspace, Philips Healthcare Nederland B.V. Best, The 
Netherlands). The Agatston scoring method (130 HU) Threshold, Density 
Mode: Maximum) will be performed on the images obtained.  Curved Plane 
MPR and 3D Images of the CTA images will be extracted utilizing the 
Comprehensive Cardiac Software to evaluate the contrasted images.[3].  
Upon request from the investigators, further analysis and statistics may be 
performed.  
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13. Estimated Study Schedule 
Estimated Daily PET/CT Study Schedule #1 – 1 per day 
Session Time Task 
Setup 16:30-17:00 Instrumentation Draping  
Animal 1  
 
14:30-16:30 
16:30-16:45 
16:45-17:00 
17:00-17:05 
17:05-17:35 
17:35-17:50 
17:50-18:20 
18:20-19:00 
Tracer Administration/Uptake 
Transfer from LARC to IUH 
Start Beta-Blockade 
Attenuation CT 
Gated Cardiac PET 
Static Abdominal PET 
Non-Contrast CT 
Gated Contrast CT 
Cleanup 19:00-19:30 Instrumentation Decontamination 
Estimated Daily PET/CT Study Schedule #2 – 2 per day 
Session Time Task 
Setup 16:30-17:00 Instrumentation Draping  
Animal 1  
 
14:30-16:30 
16:30-16:45 
16:45-17:00 
17:00-17:05 
17:05-17:35 
17:35-17:50 
17:50-18:20 
18:20-19:00 
Tracer Administration/Uptake 
Transfer from LARC to IUH 
Start Beta-Blockade 
Attenuation CT 
Gated Cardiac PET 
Static Abdominal PET 
Non-Contrast CT 
Gated Contrast CT 
Animal 2  
 
16:30-18:30 
18:30-18:45 
18:45-19:00 
19:00-19:05 
19:05-19:35 
19:35-19:50 
19:50-20:20 
20:20-21:00 
Tracer Administration/Uptake 
Transfer from LARC to IUH 
Start Beta-Blockade 
Attenuation CT 
Gated Cardiac PET 
Static Abdominal PET 
Non-Contrast CT 
Gated Contrast CT 
Cleanup 21:00-21:30 Instrumentation Decontamination 
 
14. Statistics and Reporting 
Evaluate image data for endpoints will be conducted in collaboration between 
respective scientists listed on the protocol, unless otherwise indicated. 
15.  Literature References  
1. Dandekar, M., J.R. Tseng, and S.S. Gambhir, Reproducibility of 18F-FDG 
microPET studies in mouse tumor xenografts. J Nucl Med, 2007. 48(4): p. 
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2. Studholme, C., D.J. Hawkes, and D.L.G. Hill, A normalized entropy measure 
for multimodality image alignment. Proc SPIE Medical Imaging 1998. 3338: p. 
132-143. 
3. Otton, J.M., et al., A method for coronary artery calcium scoring using 
contrast-enhanced computed tomography. J Cardiovasc Comput Tomogr, 
2012. 6(1): p. 37-44. 
16. Deliverables, Statistics and Reporting 
Statistical analysis and interpretation of the results is the responsibility of the 
sponsor, unless stated otherwise. 
 
IIBIS Statements of Study Conduct 
17. Animal Care and Use Statement 
All procedures in this protocol are in compliance with the U.S. Department of 
Agriculture’s (USDA) Animal Welfare Act (9 CFR Parts 1, 2, and 3); the Guide for 
the Care and Use of Laboratory Animals, Institute of Laboratory Animal 
Resources, National Academy Press, Washington, D.C., 1996; and the National 
Institutes of Health, Office of Laboratory Animal Welfare.  Whenever possible, 
procedures in this study are designed to avoid or minimize discomfort, distress, 
and pain to animals.   
18. Alteration of Design 
Prior to making changes to the approved protocol, the Lead Scientist or Alternate 
will consult the Sponsor as appropriate.  The date that sponsor approval is 
received will be documented in all amendments.   
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19. Regulatory Compliance 
This non-clinical laboratory study is not intended to be conducted in full 
accordance with the United States Food and Drug Administration (FDA) Good 
Laboratory Practice (GLP) regulations, 21 CFR Part 58, but will be conducted in 
accordance with IIBIS standard operating procedures. 
20. Veterinary Care/Treatment 
This study will comply with all applicable sections of the Guide for the Care and 
Use of Laboratory Animals (National Research Council 1996).  Wherever 
possible, procedures used in this study are designed to avoid or minimize 
discomfort, distress, and pain to animals.  All procedures are described in this 
study protocol or in written laboratory procedures.  These procedures are based 
on the most current available technologies concerning proper laboratory animal 
use and management. 
21. Palliative and Prophylactic Measures 
Following study distribution, the study director and sponsor/designee (if possible) 
will be included in discussions of palliative and prophylactic procedures 
(nonlife-threatening conditions, including suspension of dosing and removal of 
animals from study) recommended by the attending veterinarian.  Final authority 
for decision making will be with the Laboratory Animal Veterinarian. 
22. Reports 
22.1. Interim Report 
An electronic copy of the interim report, if applicable, will be available to the 
sponsor.   
22.2. Final Report 
An electronic copy of the final report, if applicable, will be available to the 
sponsor.   
23. Record Retention 
The raw data, documentation, specimens, the protocol, and any study related 
materials requested in section 1 for this study will be stored in the IIBIS archives 
for at least 1 year after study finalization.  The sponsor will be responsible for the 
maintenance of the test and control article reserve samples.   
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APPENDIX B 
PROTOCOL FOR DISPERSION OF VASCULAR SMOOTH MUSCLE CELLS 
(SMC) 
Michael Sturek Ph.D, MLM, 8/19/13, MLM SLD, 07/25/14 
 
Current Date        -       -             Initials_______       
 1. Conduit coronary arteries of swine are typically used.  The artery is classified 
as proximal, middle, and distal thirds.  At euthanasia/tissue collection, grossly 
dissect vessels by first locating vessel and then making a transverse cut through 
myocardium near ostium.  Remove entire length of conduit artery with minimal 
adjacent cardiac muscle, fat, etc. attached.  Place the tissue into wide-mouth 
bottle containing »50-75 ml ice-cold 2CaNa.  Place immediately into cooler filled 
with ice. (NOTE: in the case of overnight transport, store tissue in EH storage 
media on ice.) 
[Animal:  Pig#               , Age             , Time dead                , Misc.                  ] 
[Portion of artery:  Proximal      , Middle      , Distal         
Artery:  LAD___ RCA        CFX       Other?________]  
[Date         -        -        , Time of storage           ] 
 
 2.  Clean artery of adherent connective tissue, fat, cardiac muscle, etc. in cell 
culture hood in 100 x 20 mm culture dish in »30 ml Low Ca. (see COR 
OC_METv3.docx)  Treat artery gently (do not stretch excessively, if possible).   
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**At this point, the artery can be stored in the refrigerator in storage media 
for 2-5 days, if necessary. 
[Storage media = EH + PS] 
[In refrigerator:  Date         -        -          Time           ] 
 
 3.  Cut open artery longitudinally to reveal lumen. Pin down the artery with the 
lumen facing up in a 30 ml Sylgard jar with 2 mL Collagenase solution.  
(Approximately a 1 cm2 area of vessel is enough to yield several million SMC.)  
Pin the artery segment on all corners and at the middle to increase surface area.   
 
 4. Place jar in 37° C shaking water bath (100 strokes/min; 5.5 on dial) for 60 min. 
The jar should be placed so that the long axis of the vessel segment is parallel 
with the direction of the shaking.   
[Collagenase batch:  Date made:         -        -        , Made by:                          ] 
[Dispersion 1:  Date         -        -        ,  
Time started                     , Time ended                     ] 
 
5.  Aspirate supernatant and pipette over artery several times to loosen isolated 
CSM.  Place drop of supernatant in 35 mm petri dish on microscope and 
observe.  (At this point expect mostly connective tissue, endothelial cells (EC), 
etc., but few CSM.  EC are round and clump together in bunches.) Note 
appropriately and either:  1) discard_____, 2) save in 15 ml tube for immediate 
fura-2 or patch-clamp studies_____.   If #2, transfer supernatant to 15 mL conical 
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tube and clearly label with pig number and cell fraction. Centrifuge at 900 rpm 
(Not RCF) for 4 min, remove supernatant (Be careful not to aspirate the 
pellet!), then resuspend pellet in 1 mL of freshly prepared 0.02%BSA in 2CaNa 
(20 mg BSA/10 mL 2CaNa). Add 2.5μL fura-2 AM and triturate several times. 
Place in 37° C water bath for ~30-45 mins.   
 Cell fraction: ______________ (Ignore this section if discarded) 
[Dye: Fura-2____, Other_____ Dye concentration               ]  
[Loading:  Date         -        -        ,  
Time started                , Time ended                      ] 
 
6.  Add another 2 mL Collagenase solution to Sylgard jar and repeat steps 4 and 
5 until isolation is complete.  
 Step 4: 
 [Dispersion 2:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
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 Step 4: 
 [Dispersion 3:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
 
7. Centrifuge cells at 900 rpm for 4 min, resuspend in EH solution and put in 37° 
C water bath for ~20 min.  
 [Time started                , Time ended                      ] 
 
8. Centrifuge cells at 900 rpm for 4 min, resuspend in 0.02%BSA in 2CaNa and 
chill on ice. Wrap tubes in foil to protect from light exposure.  
 
NOTES: 
1. All steps following fura-2 loading, CSM are light-sensitive. When possible, 
minimize exposure to light.  
2. "Overnight dispersion" - It is also possible to disperse by exposing cells to 2 
mL collagenase in bottle at room temp. for »8-10 hours. 
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APPENDIX C 
EXPERIMETNAL SOLUTIONS 
8-20-13                                             Collagenase (in Low Ca) 
 
Component 
 
Concentration 
 
20 ml tot. 
 
10 ml tot. 
 
Stock 
Collagenase, 
CLS II 
300 U/mL 20 mg 10 mg 
300 U/mg 
(04-12-12, Worthington) 
BSA (Fraction V) 0.2% (wt/vol) 40 mg 20 mg (09-94, Sigma-Aldrich) 
Soybean Trypsin 
Inhibitor Type SI 
0.1% 20 mg 10 mg 
2.17 mg trypsin/mg 
(03-04-14, Worthington) 
DNase I, Type IV 459 KUnitz/mL 4 mg 2 mg 
2297 KUnitz/mg 
(06-04-14, Sigma-Aldrich) 
 
[Batch:  Date made:         -        -        , Made by:                                          ] 
1.  Adjust pH of Low Ca to 7.55, then add collagenase and pH will be exactly 7.40.  Filter. 
2.  Make in 10-20 ml quantities.  Each isolation requires at least 4-6 ml collagenase.  Remaining 
collagenase solution may be frozen at -20° C for up to 10 days. 
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8-3-14                                         2 CaNa 
 
 Components 
 
 Conc. (mM) 
 
 1000 ml total 
 
CaCl2 
 
2 
 
20 ml of 0.1 M 
 
NaCl 
 
138 
 
138 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
5 
 
5 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
 
NOTES: 
1. Sterile solutions all contain PS and are sterilized by filtration through Millex-GS 0.2 μm filter or 
Millipore Stericup apparatus.  
2. Penicillin Streptomycin (PS) 100 mg/ml (100 U/ml) is added in a 1:100 (vol:vol) ratio to yield a    
1% PS solution. 
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7-9-87                                             Low Ca 
 
 Components 
 
 Concentration (mM) 
 
 1000 ml total 
CaCl2 0.5 5.0 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
 
NOTES: 
 1.  Low Ca is exactly like EH, except that the Ca concentration is only 0.5 mM, and no horse 
serum is used. 
 2.  Low Ca with horse serum may be used to facilitate acquisition of a seal when doing patch-
clamp studies. 
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 7-9-87                            EH (aka Storage media) 
 
 Components 
 
 Concentration (mM) 
 
 1000 ml total 
CaCl2 2.0 20 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
Horse Serum 2% 20 ml 
 
NOTES: 
 1. EH media is a type of Eagle's Minimal Essential Medium (EMEM), but also has HEPES as a 
pH buffer, so that bubbling the solution with O2 is not necessary for maintenance of pH. 
  2. Sterile-filter under laminar flow hood with Millipore Stericup system.  
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8-4-14                                           2Ca80K 
 
 Components 
 
 Conc. (mM) 
 
 1000 ml total 
 
CaCl2 
 
2 
 
20 ml of 0.1 M 
 
NaCl 
 
63 
 
63 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
80 
 
80 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
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8-4-14                                           2Ba80K5Na 
 
Components 
 
Conc. (mM) 
 
1000 ml total 
 
BaCl2 
 
2 
 
20 ml of 0.1 M 
 
LiCl 
 
63 
 
63 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
80 
 
80 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
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APPENDIX D 
ORGAN CULTURE OF PIG CORONARY ARTERY RINGS TO INDUCE 
CALCIFICATION: 7-10 DAYS 
Mikaela McKenney, Umut Ulge, 07/23/14 
 
1. Euthanasia per standard protocol. With sterile gloves and sterile tools, 
remove heart with pericardial sac intact. 
 
2. Lay heart on inside of paper from sterile glove pack and remove the 
pericardial sac with sterile tools. 
 
3. Thoroughly rinse the heart with ice-cold sterile-filtered 2CaNa + 2% P/S. 
 
4. Transfer rinsed, sterile heart to a sterilized metal stray for gross dissection of 
the coronary arteries. 
 
5. Grossly dissect (“chunk” with surrounding myocardium) the coronary arteries 
and place in individual appropriately pre-labeled tubes of 2CaNa + 2% P/S. If 
possible, have a non-sterile partner to open and close the tubes and cooler. 
Tubes should be kept on ice at all times.  
 
6. Transfer collected specimens pack to the lab on ice for dissection under the 
sterile laminar flow hood.  
 
(see Cell culture etiquette v3-1.doc for general guidelines for the use of 
cell culture facility) 
 
7. Open the hood and turn off the U.V. first, then clean the surface with 70% 
EtOH. Perform this step first before you prepare other materials to allow for 
proper air flow and sterility of the hood.  
 
8. Fine dissection of coronary rings can take time. Always keep tissue and 
solution on ice. To keep “sterile” technique, fill a large weigh boat with ice and 
wrap with cling plastic wrap, then generously spray with 70% EtOH before 
placing under the hood.  
 
9. Thaw a frozen aliquot of 50 mL sterile-filtered Low Ca solution. Fine 
dissection should be performed in this solution within a 100x20 mm culture 
dish placed on top of ice weight boat.  
(Culture dish may be filled with Sylgard and to aid in dissection) 
*Roboz magnifying surgical loupes can be worn to aid in the fine dissection 
process. 
**Tools must be sterile and gloves should be sprayed with 70% ethanol. 
 
10. After setup is complete, spray the surface of the hood with 70% EtOH again 
before exposing the sterile tissue.  
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11. Under the hood, remove grossly dissected artery from its designated 50 mL 
tube and place in the ice-cold Low Ca solution in the sterile culture dish. 
Finely dissect coronary artery from myocardium and adventitia carefully and 
gently. Try not to nick the artery, as this will influence changes to the vascular 
structure in culture. Blunt dissection technique can help avoid this.  
 
**At this point, the cleaned artery can be cold-stored at 4°C in sterile-
filtered EH solution for up to 5 days 
 
12. As the cleaned vessel rests in ice-cold Low Ca solution (this may be replaced 
as needed during the dissection process), prepare a 6-well plate with 4-5 mL 
of sterile phosphate-buffered saline (PBS) per well.  
 
13. Cut the cleaned artery into 2-4 mm rings and place each artery in the first well 
(top left) of PBS in the 6-well plate.  
 
14. Allow rings to sit in PBS for ~30 seconds then transfer to the next well (top 
middle). Transfer each ring separately and allow excess solution to drip off of 
the ring into the previous well before transfer. Continue to transfer clockwise 
until all rings have gone through the complete 6-well serial “sterilization”.  
 
15. Prepare a 12-well plate for culture. (Depending on how the experiment is 
designed, one may need more than one plate.). Each well should be filled 
with 2 mL of culture media 
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CULTURE MEDIA FOR INDUCTION OF IN VITRO CORONARY ARTERY 
CALCIFICATION: Low-glucose DMEM + 3.8 mM NaPhos + 7.5 U/mL Alkaline 
Phosphatase: (40 mL total volume) 
 
Ingredient Stock Conc 
Final 
Conc Dilution For 40 mL 
Low-glucose Dulbecco’s 
Modified Eagle’s Medium 
(DMEM) + 1% PenStrep (P/S) 
1X 1X 1:1 39.5 mL 
Sodium Phosphate  
(NaPhos) 760 mM 3.8 mM 1:200 200 uL 
Alkaline Phosphatase 
Enzyme  
(ALP) 
1000 
U/mL 7.5 U/mL 1:133 300 uL 
DMEM + 1% P/S: add 50 μL P/S(100X) to 500 mL DMEM stock(Sigma).  
*LABEL & DATE the DEMEstock bottle.  
NaPhos solution: 17.3 g monobasic(NaH2PO4), 87.3 g dibasic(Na2HPO4),  
1 mL ddH20, then sterile syringe filtered 
ALP: 1000 U/mL frozen stock (Promega) 
**Do not keep a stock of calcification media for more than one day. 
(NaPhos and ALP should be prepared fresh each media change)  
 
 
16. Set aside the desired number of rings for Day 0/”Fresh” measures: 
Potential measures for OC time course: 
a. Histopathology: formalin fix 
b. Protein expression: flash freeze 
c. fura-2 Ca imaging: cold-store in EH until experiments 
d. isometric ring tension measures: cold-store in EH until experiments 
 
17. Transfer a single coronary ring into a single well of the prepared 12-well plate.  
 
18. Cover each plate and label appropriately with pig number, date, and culture 
media for particular rows or columns of wells.  
 
19. Transfer plates to the 37°C incubator. Check that the CO2 is set to 4.6% and 
that the tray at the bottom of the incubator is full of distilled water.   
 
20. Media should be changed every 2-3 days. Note the color of the media daily 
as this is an indicator of pH. Media should appear pink-red. A shift towards 
acidity (closer to yellow) or alkalinity (closer to dark purple) would indicate the 
tissue is deprived of something. Acidity is more common and may be seen 
close to 3 days in the same media. This indicates cell metabolism and time to 
change media. RECORD DATE OF MEDIA CHANGE.  
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**Media should be changed under the hood using sterilized glass 
pipettes and vacuum system. Avoid catching the artery ring on the 
vacuum pipette tip as this will damage the arterial wall and affect the 
culture.   
 
21. For each time point, remove the necessary number of rings per measure. 
NOTE & DATE wells from which rings were removed.  
 
22. Continue to change media every 2-3 days until culture is complete.  
 
 
 
 
 
 
 
NOTES: 
1. All solutions used should be sterile filtered with a 0.22 μm filter system: 
syringe filter 
    (FisherBrand), Stericup, Steriflip (Millipore).  
2. Larger coronary rings (domestic pigs) may need closer to 10-14 days in 
calcification media to  
    induce in vitro coronary artery calcification. 
3. “Low-glucose” DMEM is similar to physiologic blood glucose levels (1 g/L). 
4. If freezing freshly dissected rings for protein or gene expression, always tend 
to those  
    specimens first before starting the culture.  
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APPENDIX E 
QUANTIFICATION OF MEDIAL AREA (IMAGEJ, NIH) 
NKR 07/2013 
1. Once you have set the focus and zoom on the camera, take a picture of 
the 1000-micron scale with the 2X lens and the 10X lens. (NOTE: once 
you have set the focus and zoom on the camera you cannot adjust it, as 
your scale will not reflect any adjustments made) 
 
2. Open ImageJ 
 
3. Then open the 2X scale image. 
4. Click the line box in the menu:  
 
5.  Draw a line from one end of the scale to the other, like this:  
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6. Then click set scale:     
 
 
7. A box will pop-up, you should adjust your settings so they look like this 
(Note: the distance in pixels may differ, as long as you are close, the 
measurements will work):  
 
  
Click ok. 
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8. Open a coronary ring (2X image) that you would like to measure. 
 
9. Zoom in as much as you like, but you must be able to view the whole ring. 
 
 
10. Click Process, then click Sharpen: 
 
 
11. Click the Polygon selection tool :  
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12. Trace the external elastic lamina (one-click to start the line, double-click to 
end): 
 
 
13. Click the letter “M” or ”Ctrl + M” on your keyboard, if it does not work, you 
can go to Analyze, then click measurement in the Menu bar. 
 
14. A measurement box will pop-up and it will already have the area of the 
circle: 
 
15. Click somewhere outside the selection area to reset the measuring tool, 
then trace the internal elastic lamina: 
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16. Click “M” to measure, now the measurement box should have two 
measurements: 
 
 
17. If you subtract the 1st number (area of Media + Lumen) minus 2nd number 
(Lumen), you will calculate the area of the medial layer. 
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QUANTIFICATION OF COLLAGEN AREA (IMAGEJ, NIH) 
NKR 07/2013 
1. Once you have set the focus and zoom on the camera, take a picture of 
the 1000-micron scale with the 2X lens and the 10X lens. (NOTE: once 
you have set the focus and zoom on the camera you cannot adjust it, as 
your scale will not reflect any adjustments made) 
 
2. Open ImageJ 
 
3. Then open the 2X scale image. 
4. Click the line box in the menu:  
 
5.  Draw a line from one end of the scale to the other, like this:  
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6. Then click set scale:  
 
 
7. A box will pop-up, you should adjust your settings so they look like this 
(Note: the distance in pixels may differ, as long as you are close, the 
measurements will work):  
 
  
Click ok. 
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8. Open a coronary ring (2X image) that you would like to measure. 
 
9. Zoom in as much as you like, but you must be able to view the whole ring. 
 
10. Click Process, then click Sharpen: 
 
 
11. Then click Image, then Adjust, then Color Threshold: 
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12. Set the color range from 0 to 62, this will exclude all of the red, yellow, and 
orange colors, thus leaving the collagen stained areas. Also make sure all 
three fields are “checked” Pass: 
 
 
13. Then click Image, Type, then 8-bit: 
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14. Then click Image, Adjust, then Threshold: 
 
 
15. Slide both sliders until what you want to measure is colored red, this is what 
the program will analyze. Here is an example: 
 
16. Click the Polygon selection tool :  
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17. Since, we want medial collagen, trace the external elastic lamina (one-click 
to start the line, double-click to end): 
 
 
18. Click Analyze, then click Analyze Particles 
 
 
19. A box will pop-up, use this criteria: 
 
Click Ok. 
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20. Two windows will pop-up. One will have the area of all of the particles and 
one will show you which particles the program measured. I just check to 
make sure the program has not analyzed any random particles outside my 
region of interest. 
 
21. Save the Results window by clicking on the Results sheet and then clicking 
File and Save As… 
 
 
22. It should save as an Excel file. When you open the file, you can use a SUM 
equation to sum up all of the areas that ImageJ has calculated. 
 
23. Repeat steps 16-22, except trace the internal elastic lamina, so the lumen is 
now the area of interest. This will pick up any random lumen collagen, which 
you can then subtract from the first measurement. 
 
 
24. By subtracting the 1st number (Sum of area of Collagen in Media and 
Lumen) minus 2nd number (Sum of area of Collagen in Lumen), you will 
calculate the area of Collagen within the medial layer.  
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APPENDIX F 
PROTOCOL FOR FLOW CYTOMETRY IDENTIFICATION OF CSM 
PHENOTYPES FROM FRESHLY DISPERSED PIG CORONARY ARTERIES: 
Mikaela McKenney, Heather O’Leary, Ph.D. 
08/02/2014 
 
1. From freshly dissected coronary arteries or coronary rings from organ culture 
experiments.  
 
2. Enzymatically isolate CSM from coronary artery/rings as described in 
CORSMC1_v2.doc.  
a. NOTE: keep ALL cell fractions from dispersion. 
b. Stop before fura-2 loading step. 
 
3. Combine all cell fractions, spin down, and remove supernatant. 
 
4. Resuspend in Cytofix/Cytoperm solution (BD, San Jose, CA). Triturate 
suspension several times. 
**At this point, cells can be stored in fridge until time of flow 
experiments.  
 
The following Flow Cytometry methods are conducted in the Department of 
Microbiology and Immunology, Broxmeyer lab, contact: Heather O’Leary, Ph.D.:  
         haoleary@iupui.edu  
 
5. Cell viability is determined by trypan blue exclusion and counting of cells on a 
hemacytometer.  
 
6. Preps with an initial viability of 85% or above are subsequently fixed and 
permeabilized  (BD Cytofix/Cytoperm, San Jose, CA).  
 
7. Cells are washed from fixative and should  remain in permwash for the 
remainder of the staining protocol. Markers of phenotypic smooth muscle 
group to determine phenotypic populations: Amount of antibody was titrated 
based on isotype controls but were within the manufacturers suggested guide 
lines. A common cocktail was made for all samples Containing matched 
isotype control or specific antibodies of interest. 
 
a. smooth muscle myosin heavy chain (SM-MHC) 
i. polyclonal rabbit anti-SM-MHC, Alex Fluor 488, Bioss, Woburn, 
MA) 
 
b. α-smooth muscle actin (SMA) 
i.  (monoclonal mouse anti-human SMA. APC, R&D systems, 
Minneapolis, MN) 
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c. runt-related transcription factor 2 (RUNX2) 
i. (monoclonal mouse anti-RUNX2 antibody ab76956, abcam, 
Cambridge, MA  
ii. DyLight 405 ChromPure Rabbit IgG, Jackson ImmunoReseach 
Laboratories, West Grove, PA 
 
8. Cells were stained for 30 minutes and washed in permwash followed by 
wash, and resusension, in PBS (~200UL).  
 
9. Cells were run on an LSRII machine in the IU simon cancer center flow 
cytometry core running FACSDiva software. Gates were set up according to 
isotype controls 
 
10. Analysis of samples was performed using FLOWJO software and 
gates/subgates were determined by isotype controls and were identical for all 
samples to ensure consistency.  
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